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ABSTRACT 
Gliomas are the most common tumors of the central nervous system in adults. 
Glioblastoma, the most aggressive form, has a median survival of 15 months regardless 
of the standard treatment with surgery and temozolomide-based radiochemotherapy. 
Therefore, it is imperative to improve treatment options for patients with glioblastoma.  
 
It has been suggested that the putative tumor stem cells in brain tumors are responsible 
for glioma initiation, development and resistance to conventional therapy and therefore 
may be a potential target for novel therapy. 
 
By searching for stem cell gene expression signatures in human high-grade glioma 
cultures, two novel subsets (type A and type B) of glioblastoma cultures were identified 
with gene expression profiles similar to the recently described TCGA 
proneural/classical/neural and the mesenchymal subsets, respectively. The two subsets 
of cultures have different capacities in terms of tumorigenic potential, sphere forming 
ability and distinct tyrosine kinase inhibitor sensitivity profiles. The findings that the 
resistance of type A cultures to tyrosine kinase inhibitor mono-treatment is SOX2-
dependent and can be overcome by a combination of treatments with PDGFR and 
IGF1-R inhibitors provide a novel strategy for tumor stem cell-targeting therapy. 
 
A set of markers defining neural stem cells and pluripotent embryonic stem cells were 
tested on a series of human glioma tissues. Results demonstrated that besides 
deregulated expression of neural and pluripotent stem cell regulatory proteins, high-
grade gliomas also show expression of mesodermal- and endodermal-specific 
transcription factors together with neural proteins. In vivo xenograft experiments 
indicated that the presence of pluripotency markers is dependent on signals from the 
tumor microenvironment.  
 
An experimental mouse glioma model with human PDGFB overexpressed in astrocyte 
and astrocyte progenitor cells on a p53 null background was used for studying 
epigenetic changes in mouse brain tumors and in neural stem/progenitor cells during 
the pre-neoplastic stage. DNA hypomethylation and elevated Histone3 Lysine9 di-
methylation (H3K9Me2) were detected not only in the tumors but also in samples of 
the adult frontal brain lateral ventricular wall (LVW) and in neurosphere cultures 
respectively, from the hGFAPpPDGFB/Trp53 null (B+p53-/-) brain during the pre-
neoplastic stage. Thus, non-neoplastic but epigenetically disturbed LVW cells might be 
early targets of transformation in the development of glioblastoma. 
 
Taken together, this work provides some new insights into stem cell related 
mechanisms involved in glioma development. Therefore, targeting brain cancer stem 
cells presents a new and potentially more effective therapy for glioma. 
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1 INTRODUCTION 
 
1.1 STEM CELLS 
In a way, we may say that an organism’s life begins with stem cells. In other words, the 
stem cell could be described as the “origin of life”. Stem cells are undifferentiated and 
self-renewing cells that have the ability to give rise to multiple specialized cell types 
(differentiated cells) that carry out specific functions in the body. Stem cells play 
important roles starting from embryonic development (embryonic stem cells) through 
to adulthood (adult stem cells).  
 
In terms of the differentiation potential, stem cells could be classified into totipotent, 
pluripotent, and multipotent stem cells (Fig 1). When a sperm and an egg meet, they 
form a fertilized egg called zygote. The zygote has the potential to form an entire 
functional organism and also the placenta. This cell is totipotent. When the cell 
continues to divide, about one week after fertilization, a small ball-like structure with a 
few hundred cells is formed. This is the blastocyst. The blastocyst has two layers. The 
outer layer is termed the trophoblast and will form the placenta, while a clump of cells 
inside the ball called the inner cell mass, will give rise to all the cell types of the body. 
Embryonic stem cells are derived from the inner cell mass of the blastocyst. As 
embryonic stem cells can form nearly any tissue of the body, they are described as 
pluripotent, not totipotent. When the pluripotent cells continue to divide, at around two 
weeks after fertilization, the cells differentiate into three primary germ layers 
(ectoderm, mesoderm, endoderm), and each of these layers will give rise to a different 
set of cell types. Cells from ectoderm will form skin, nervous system and parts of face 
and neck; cells from mesoderm will form muscles, blood, blood vessels and connective 
tissues; cells from endoderm will form the digestive and respiratory tracts including 
pancreas and liver. These less plastic and more differentiated stem cells within a 
specific tissue type are multipotent stem cells. An adult stem cell is a multipotent stem 
cell, and plays an important role in the growth, maintenance and repair of the body. 
Adult stem cells have been found in many different tissues such as blood, blood 
vessels, brain, skin, muscles, teeth, heart, gut, liver and breast. 
 
Because of this self-renewal capacity and this plasticity and potential to develop into 
almost any type of cell, stem cells offer a great hope for potential application in 
regenerative medicine and tissue replacement therapy following injury or disease. 
 
 
1.1.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are cells from the inner cell mass of the blastocyst. Two 
defining properties of ESCs are pluripotency: the capacity to give rise to cells 
representing all the three germ layers; and self-renewal capacity: the ability to generate 
a new pluripotent stem cell when undergoing division. 
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Figure 1. Classification of stem cells [modified from (Banerjee, 2011)] 
 
 
1.1.1.1 Mouse embryonic stem cells 
 
Mouse ESCs (mESCs) were first isolated from pre-implanted mouse blastocysts in 
early 1980’s (Evans and Kaufman, 1981; Martin, 1981). With the help of leukemia 
inhibitory factor (LIF) and bone morphogenetic protein 4 (BMP4), mESCs could be 
propagated in vitro, while retaining pluripotency (Bradley et al., 1984; Smith et al., 
1988; Williams et al., 1988; Ying et al., 2003). The application of homologous 
recombination technology to mESCs makes it possible to manipulate the whole mouse 
genome and to study gene function in vivo in an intact organism (Capecchi, 2005).  
 
1.1.1.2 Human embryonic stem cells 
 
The derivation of human embryonic stem cells (hESCs) from human blastocysts 
provides a useful system to study early human embryonic development and also a 
valuable tool for potential application in regenerative medicine (Thomson et al., 1998). 
Similar to their mouse counterpart, cultured hESCs keep their self-renewal ability 
during the undifferentiated stage and the pluripotent capacity to differentiate into any 
cell type in the body.  However, hESCs and mESCs differ in their morphology and 
growth rate. Further, hESCs need the basic fibroblast growth factor (bFGF) and 
activin/nodal for in vitro maintenance (Beattie et al., 2005; Xu et al., 2005). Several 
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hESC lines have been established and have shown no signs of differentiation, no 
chromosomal defects, while presenting self-renewal and pluripotent properties, high 
telomerase activity and the ability to form teratoma in immune deficient mice. These 
hESC lines are FDA-approved for research and clinical trials (Lu et al., 2009; Sharp et 
al., 2010). 
 
1.1.1.3 Transcriptional regulatory network in ESCs 
 
In ESCs, the self-renewing and pluripotent state is largely controlled by the core 
transcription factors Oct4, Sox2 and Nanog (Ng and Surani, 2011; Young, 2011).  
 
Oct4, also known as POU5F1, belongs to the POU transcription factor family (Scholer 
et al., 1990).  It recognizes an 8-bp DNA sequence found in promoter and enhancer 
regions of many genes. During early embryo development, the expression of Oct4 is 
mainly restricted to totipotent and pluripotent cell stages, that is, the zygote and the 
inner cell mass of the blastocyst (Pesce and Scholer, 2001). The essential role of Oct4 
in development was first shown by studying the Oct4 knock-out mouse. The Oct4 
deficient embryo failed to develop beyond the blastocyst stage due to the lack of a 
pluripotent inner cell mass (Nichols et al., 1998). Further, by quantitatively 
manipulating the expression level of Oct4, it was shown that ESCs need a critical level 
of Oct4 to maintain the stem cell state. A higher level would force ESCs to differentiate 
to mesoderm and endoderm lineages, while a lower level would lead to 
trophectodermal cells. Only the “normal” Oct4 level maintains the pluripotent and 
undifferentiated ESCs state (Niwa et al., 2000). It seems that Oct4 lies at the center of a 
gene regulatory program that maintains the pluripotency of ESCs.    
 
Nanog is another key transcription factor that is involved in the maintenance of ESCs 
pluripotency. Nanog was cloned by two independent research groups simultaneously 
(Chambers et al., 2003; Mitsui et al., 2003). It is a homeobox transcription factor, 
dominantly expressed in the inner cell mass of the blastocyst. Germline loss of Nanog 
leads to early embryonic lethality, and down-regulation of Nanog will induce ESCs 
differentiation. 
 
Sex-determining region Y-box 2 (Sox2) belongs to the family of high mobility group 
proteins (HMG). Besides its role in neurogenesis, Sox2 also takes part in the regulation 
of ESCs. Knock-out of Sox2 in mice is embryonic lethal (Avilion et al., 2003). 
Interestingly, overexpressed Oct4 could rescue the pluripotency of Sox2-null ESCs 
(Masui et al., 2007), indicating that the function of Sox2 in maintenance of the ESCs 
pluripotent state is through regulation of Oct4. 
 
By using chromatin immunoprecipitation (CHIP) combined with genome-wide 
mapping technology, common target sites in the regulatory elements of Oct4, Sox2 and 
Nanog genes have been found (Boyer et al., 2005; Loh et al., 2006). It was suggested 
that Oct4, Sox2 and Nanog might form a regulatory circuit that governs pluripotency of 
ESCs. In this circuit, the three transcription regulators not only regulate each other, but 
regulate themselves as well. Additional pluripotency-related factors such as Smad1, 
Stat3 and Klf4 are also linked to this network (Ng and Surani, 2011). 
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The comparison between tumor cells and ESCs has for a long time been of great 
interest. The high proliferative capacity and phenotypic plasticity of tumor cells 
resemble much of the self-renewal capacity and pluripotency of ESCs. Embryogenesis 
is mirrored in an abnormal way by tumor development. A comprehensive gene set 
expression analysis suggested that the core ESCs signature (Oct4, Nanog, Sox2) and 
also their downstream target genes are closely related to histologically poorly 
differentiated aggressive human tumors, such as high-grade malignant estrogen 
receptor-negative breast cancer, glioblastoma and high-grade malignant bladder 
carcinoma (Ben-Porath et al., 2008). Other reports, including our own have also 
demonstrated that the pluripotent stem cell signature correlates with increased 
malignancy in human glioma (Holmberg et al., 2011). Respective down-regulation of 
Sox2, Nanog and Oct4 function could reduce the self-renewal capacity of human 
glioma cells (Du et al., 2009; Hagerstrand et al., 2011) and limit their tumor initiating 
potential in mouse brain (Gangemi et al., 2009; Zbinden et al., 2010).  
 
 
1.1.2 Induced pluripotent stem cells  
Knowing the key factors that govern pluripotency of ESCs has enabled the generation 
of a new type of pluripotent stem cells, the induced pluripotent stem cells (iPSCs). 
iPSCs are adult somatic cells that have been (genetically) reprogrammed to an 
embryonic-like pluripotent state by artificial introduction of key genes and factors that 
sustain the self-renewal and pluripotency of ESCs. The first mouse iPSC was generated 
in Yamanaka’s lab in 2006 (Takahashi and Yamanaka, 2006). One year later and at 
about the same time, human iPSCs were generated independently by the Yamanaka’s 
group and also by Thomson’s group but with different combinations of key factors. 
Oct4, Sox2, Klf4 and c-Myc were used by the Yamanaka group, while Oct4, Sox2, 
Nanog and Lin28 were used by the Thomson group (Takahashi et al., 2007; Yu et al., 
2007).  
 
The generation of human iPSCs is a milestone in the stem cell research field. It 
introduced an approach not only for creating a new model system of human diseases 
but also for potential use in personalized regenerative medicine. Compared to hESCs, 
human iPSCs have similar phenotypes regarding morphology, gene expression pattern, 
and differentiation potential to all three germ layers when assayed by embryoid body 
formation in vitro and teratoma formation in vivo (Okita et al., 2007). Moreover, iPSCs 
overcome the ethical obstacles and pave the way for using human cells for custom-
tailored cell-based therapy. So far, iPSCs have been generated from different cell types 
such as dermal fibroblasts, neural stem cells and keratinocytes (Aasen et al., 2008; Kim 
et al., 2009; Lowry et al., 2008).  
 
Although remarkable progress has been made in reprogramming techniques over the 
years by using synthetic modified peptides or mRNA instead of retroviral or other 
genetic vectors for transduction, one should still bear in mind the risk of tumorigenicity 
of iPSCs when applying them into clinical settings. There are trials exhibiting 
promising evidence (Hanna et al., 2007; Raya et al., 2009), but iPSCs have the risk of 
inducing teratocarcinoma and somatic tumors (Ben-David and Benvenisty, 2011). 
More efforts need to be put into creating safe iPSC lines for future clinical applications. 
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1.1.3 Adult neural stem cells 
Adult stem cells are tissue specific, are less plastic and are in a more differentiated state 
compared to ESCs. Adult stem cells divide asymmetrically in order to give rise to cells 
of the particular tissue they reside in and also to conserve the stem cell population, as 
such are multipotent and self-renewing. Differentiated cells generated from adult tissue 
stem cells are able to replace damaged cells to recover normal tissue function. 
 
Adult neural stem cells (NSCs) are multipotent cells that reside in the adult mammalian 
brain. They are capable of long- term expansion and differentiation into neurons and 
glia. Thanks to pioneering studies decades ago, it is now very well recognized that 
neurogenesis occurs throughout life in almost all mammals including human (Altman 
and Das, 1965; Eriksson et al., 1998; Reynolds and Weiss, 1992; Richards et al., 1992).  
 
Two neurogenic regions in the brain have been characterized where adult neural stem 
cells are located and active neurogenesis takes place. One is the subgranular zone 
(SGZ) in the dentate gyrus of the hippocampus, where new dentate granule cells are 
generated; the other is the subventricular zone (SVZ) of the lateral ventricles, where 
new neurons are created and then migrate to the olfactory bulb through the rostral 
migratory stream. There are two schools on the identity and lineage relationship of 
NSCs in the brain. Alvarez-Buylla proposes that glial fibrillary acidic protein (Gfap) 
positive astrocytes in the SVZ represent the NSCs, also named B cells, from which 
transit-amplifying cells (C cells) are generated and in turn give rise to neuroblasts (A 
cells). These neuroblasts migrate along the rostral migratory stream to generate neurons 
in the olfactory bulb. Gfap+ B cells also give rise to oligodendrocytes in the nearby 
corpus callosum. Dentate gyrus neurons are generated by Gfap+ B cells in the SGZ 
(Alvarez-Buylla and Lim, 2004). Whilst, Gage (Ming and Song, 2011; Suh et al., 2007) 
proposes that the Sox2 protein expressed in non-radial cells identify active NSCs that 
give rise to neurons and glia in the adult SGZ, and it was claimed that the Sox2+ NSCs 
favor neuronal differentiation over astrocyte formation. These different views may 
reflect the coexistence of multiple types of NSCs and their plasticity in the adult brain. 
 
Although it is not unique, Sox2 is a protein marker commonly used to identify NSCs. 
Sox2 belongs to the SoxB1 group (Sox1, Sox2, Sox3) of HMG transcription factors. 
Besides being expressed in ES cells, SoxB1 proteins were found in neuroepithelial cells 
during development and in neurogenic regions in the postnatal and adult CNS (Pevny 
and Placzek, 2005). In vitro gain-of-function analyses have indicated that Sox1-3 could 
sustain the self-renewal property of NSCs, while a dominant-negative version of these 
proteins would induce NSCs to exit the cell cycle and differentiate (Bylund et al., 2003; 
Graham et al., 2003). Further, in vivo gene targeting experiments demonstrated 
defective neurogenesis in the adult brain of Sox2 deficient mice (Ferri et al., 2004). In a 
very recent paper, Sox2 has been used as a single factor to directly reprogram mouse 
and human fibroblasts into multipotent NSCs (Ring et al., 2012).  
 
The specialized microenvironments where NSCs reside are termed niches. Stem cell 
niches are comprised not only of stem cells and their progeny but also include the 
endothelial cells of the adjacent vessels and the basal lamina cells attached to stem 
cells. Within the stem cell niches, cells interact with each other, and they are exposed to 
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a variety of growth factors, and extra-cellular diffusible signals for feedback control of 
stem cell self-renewal and differentiation (Fuentealba et al., 2012). As suggested in the 
SVZ niche (Fig 2), the ependymal cells (E cells) that line the lateral ventricle are 
adjacent to Gfap+ stem cells (B cells), transit-amplifying cells (C cells) and neuroblasts 
(A cells). B and C cells also directly connect to the vasculature. Recent studies are 
indicating that the vasculature is an important component of the stem cell niche.  It has 
been shown that the dividing neural stem cells and their progeny, transit-amplifying 
cells are tightly connected with blood vessels both during homeostasis and regeneration 
(Tavazoie et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  SVZ of the lateral ventricle and neurosphere assay  
                 [modified from (Pastrana et al., 2011)] 
 
 
Due to the lack of exclusive markers for the identification of stem cells in the brain, the 
study of the NSCs is usually based on functional assays, using both in vivo labeling and 
in vitro culture. In the early 90’s, Reynolds and Weiss first cultured cells with stem 
cells properties as free-floating spheres from the adult brain, named neurospheres (Fig 
2) (Reynolds and Weiss, 1992). They microdissected out the lateral wall subventricular 
zone (SVZ) of the lateral ventricles, dissociated the tissue cells to a single cell 
suspension, and plated cells in a non-adherent culture dish in serum-free medium 
supplemented with epidermal growth factor (EGF). After several days, cells formed 
spheres of proliferating cells. The spheres could be dissociated and cultured again 
under the same conditions to form secondary and tertiary spheres, which illustrated 
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their self-renewal property. When plated on an adherent surface in combination with 
withdrawal of EGF, the cells differentiated into neurons, astrocytes and 
oligodendrocytes, which showed their multipotency. This neurosphere assay has been 
widely used in stem cell biology, as it is a simple and effective assay to identify cells 
displaying the two distinguishing functional characteristics of stem cells, self-renewal 
and differentiation. However, the individual neurosphere is not a homogeneous sphere, 
but contains a mixture of stem cells, progenitors and differentiated cells. Practically, 
some critical points should be taken into consideration when applying the neurosphere 
assay in research, for example, the cell density, which is a strict parameter for clonality. 
 
 
1.1.4 Cancer stem cells / tumor initiating cells 
The concept of cancer stem cells (CSC) comes from the comparison of normal stem 
cells and cancer cells. The key to the cancer stem cell hypothesis is that not all the cells 
in a tumor are equal. Like many normal proliferative tissues, the bulk tumor comprises  
of self-renewing undifferentiated cells as well as differentiated cells. Furthermore, only 
a limited population of stem cell-like cells within the tumor may be responsible for 
tumor initiation, maintenance, resistance to treatment and recurrence. According to the 
proposed definition from the AACR Workshop on Cancer stem cells 2006 (Clarke et 
al., 2006), “a cancer stem cell is a cell within a tumor that possesses the capacity to 
self-renew and to cause the heterogeneous lineages of cancer cells that comprise the 
tumor. Cancer stem cells can thus only be defined experimentally by their ability to 
recapitulate the generation of a continuously growing tumor.”  Therefore, the terms, 
CSC and tumor initiating cell (TIC), are interchangeably used.  
 
The putative CSC was first identifed in materials from acute myelogenous leukemia 
(AML) (Bonnet and Dick, 1997; Lapidot et al., 1994). It was demonstrated by Dick’s 
group that only the CD34+CD38- fraction of cells could initiate leukemic engraftment 
in immunodeficient mice. Years later, Clarke and his colleagues applied this idea to 
solid tumors. They showed for the first time that as few as 100 CD44+CD24- cells 
could form tumors in a xenograft assay (Al-Hajj et al., 2003). Now, more and more 
evidence has been provided for the existence of CSCs in tumors from brain, colon, 
prostate, lung, pancreas, and other tissues (Collins et al., 2005; Eramo et al., 2008; Galli 
et al., 2004; Hermann et al., 2007; Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et 
al., 2007; Singh et al., 2004). 
 
The defined CSCs should be challenged with regard to the two hallmarks of normal 
stem cells, that is self-renewal and lineage capacity. The best functional assay that 
meets these criteria is the serial transplantation assay in immune-deficient mice in vivo. 
As a surrogate functional assay to identify CSCs in vitro, the tumor sphere assay, which 
is adopted from the neurosphere assay used for NSC research, has been employed quite 
often (Al-Hajj et al., 2003; Galli et al., 2004; Singh et al., 2004).  
 
The CSC hypothesis proposes a hierarchical model of tumorigenesis, which challenges 
the previous stochastic or clonal model of evolution (assuming that the majority of 
tumor cells can act as TICs). The hypothesis may provide some explanations for the 
relapse of tumors that showed effective therapy response initially, since the CSCs 
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might survive through the so-called initially effective treatment phase that only ablated 
the non-tumorigenic tumor cells. CSCs then remain and initiate tumor formation again. 
According to this theory, a more effective cancer treatment would aim not merely at 
reducing the tumor bulk, but rather at targeting the key cells within the tumor, the 
CSCs. 
 
When the term CSC or TIC is used, it does not relate to the question of cell of origin of 
cancer. CSC and cell-of-origin are two different concepts. Cell-of-origin is the normal 
cell that acquired the first cancer promoting mutation (Visvader, 2011). Meanwhile, the 
CSC or TIC is named after its capability of initiating a tumor when transplanted in 
animal models. The term initiating is a functional description of the cells in the 
transplantation assay, which are not necessarily the cell-of-origin of cancer. The cell-of-
origin of cancer is still under debate. Any cell with abnormal proliferative property has 
the possibility to serve as a cell-of-origin of cancer. It could be a mutated tissue stem 
cell, or progenitor cell and it could be a de-differentiated tissue cell as well. Very 
recently, one study reported that during in vitro oncogenic transformation, a subgroup 
of human fibroblasts could be reprogrammed to CSC-like cells. These transformed 
CSCs could initiate and maintain tumor growth (Scaffidi and Misteli, 2011), which 
implies that the somatic cells have the potential to de-differentiate and acquire CSCs 
properties. 
 
Cancer treatments and outcomes have improved in past decades, but challenges still 
remain. The CSC hypothesis provides an attractive new strategy. Targeting CSCs might 
improve the outcome of cancer treatments. However, the CSC hypothesis is still young, 
there are lots of challenges to meet, such as the technical limitations, non-specificity of 
CSC markers (Rahman et al., 2011) and the interconversion of CSCs and non-CSCs 
within a tumor etc. (Visvader and Lindeman, 2012). An open mind should be kept 
when considering the still un-matured CSC hypothesis. 
 
 
 
1.2 BRAIN TUMORS 
According to the most recent population-based incidence statistics in the US, the 
overall incidence of brain tumors is now 18.71 per 100,000 person/year. Among those, 
7.19 per 100,000 person/year are malignant tumors (CBTRUS, 2011; Ostrom and 
Barnholtz-Sloan, 2011). Malignant brain tumors, account for only 1-2% of all cancers, 
and are considered rare, but have a high mortality rate. 
 
 
1.2.1 Histological classification of human brain tumors 
The classification of human brain tumors is mostly based on the histological features of 
each particular tumor type.  Malignant gliomas, which account for more than 70% of 
all brain tumors in adults, are similar to glia. According to the World Health 
Organization (WHO), astrocytomas are classified into four malignancy grades: 
pilocytic astrocytoma (grade I), diffuse astrocytoma (grade II), anaplastic astrocytoma 
(grade III) and glioblastoma (GBM) (grade IV) (Louis DN, 2007; Louis et al., 2007). 
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Anaplastic astrocytomas feature increased cellularity, nuclear atypia, mitotic activity 
and some microvascular proliferation; Glioblastomas further contain elaborate 
microvascular proliferations and/or necrosis. Oligodendrogliomas and 
oligoastrocytomas are divided into two grades: oligodendrogliomas, oligoastrocytomas 
(grade II) and anaplastic oligodendrogliomas, anaplastic oligoastrocytomas (grade III). 
Oligodendrogliomas seem to respond better to medical intervention than other types of 
glioma (van den Bent, 2010). Although the WHO classification is mainly based on the 
histo-morphological changes, the classification is an indication of cellular 
differentiation status, malignant potential, response to treatment and patient survival.  
 
 
1.2.2 Clinical subgroups of glioblastoma 
GBM is the most common and most malignant tumor of the central nervous system 
(CNS) in adults. The overall median survival time for GBM patients is only 15 months 
(Van Meir et al., 2010; Wen and Kesari, 2008). From a clinical point of view, GBM 
could be grouped into two categories, primary and secondary. Primary GBMs develop 
de novo, without any evidence of a less-malignant precursor lesion, but this does not 
necessarily suggest a single-step transformation. Like other tumors, primary GBMs 
result from an accumulation of genetic and epigenetic alterations. Secondary GBMs 
develop progressively from low-grade diffuse astrocytoma (grade II) or anaplastic 
astrocytoma (grade III). The diagnosis of a secondary GBM needs clinical support such 
as neuroimaging or histological evidence of a progression from a less malignant 
astrocytoma. Compared to primary GBM, secondary GBM is rare, only represents 5-
10% of all the diagnosed GBM cases. Primary and secondary GBMs constitute two 
distinct disease entities, and they display differences in terms of patients’ age at 
diagnosis, genetic and expression profiles and response to therapy (Dunn et al., 2012). 
Evidence has accumulated that primary and secondary GBMs develop through different 
genetic pathways (Dunn et al., 2012). However, from the histo-pathological side, these 
two subtypes are indistinguishable. 
 
 
1.2.3 Genomic alterations in glioma 
The development of modern molecular technologies provides the opportunities for a 
detailed description of the molecular characteristics of gliomas. The detailed molecular 
mapping of malignant gliomas could not only define more accurately the specific 
subgroups within the same WHO category, but also lay the ground work for more 
rationally designed and personalized treatment.  
 
The extensive identification of genomic alterations in gliomas has started to refine the 
classification of gliomas. Analysis of molecular markers in pathology clinics is under 
way to assist in diagnosis and predict clinical outcome of glioma patients. 
 
1.2.3.1 Chromosome 1p/19q deletions in oligodendroglioma 
 
The combined deletion/translocation of the short arm of chromosome 1(1p) and the 
long arm of chromosome 19 (19q) has been known for quite some time and linked to a 
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better prognosis and a better responsiveness of oligodendroglial tumors to certain 
chemotherapies (Bigner et al., 1999; Cairncross et al., 1998; Smith et al., 2000). 
Determination of 1p/19q status is recommended for all tumors with an oligodendroglial 
histo-morphology in routine clinical practice (Robertson et al., 2011). 
 
1.2.3.2 Activation of growth factor pathways in glioma 
 
Two decades of genomic studies of GBMs have demonstrated that both normal growth 
factor pathways and cell cycle check points are disrupted in malignant glioma. 
Recently, The Cancer Genome Atlas (TCGA) studies confirmed previously recognized 
genomic changes and also uncovered some new gene mutations in GBM (TCGA, 
2008). 
 
Over-activation of receptor tyrosine kinase (RTK) signaling pathways is one of the 
most common molecular alterations in GBM, usually caused by the amplification 
and/or overexpression of genes for both growth factors and their receptors, such as 
epidermal growth factor receptor (EGFR), platelet-derived growth factor (PDGF) and 
its α-receptor (PDGFRA). Two other RTKs altered in GBM are ERBB2 (mutated in 
8% of GBMs) and MET (amplified in 4% of GBMs). When a growth factor binds to its 
cell surface tyrosine kinase receptor, dimerization and transphosphorylation of receptor 
molecules occurs. Thus, downstream signaling pathways like PI3K/AKT and 
RAS/MAPK are activated as well. This occurs in 88% of GBMs, mediating the 
increased proliferation and survival of cells (TCGA, 2008). 
 
Amplification and over-expression of EGFR is common in primary GBM (40%), but 
rare in secondary GBM (Ohgaki and Kleihues, 2011). Recent TCGA data showed 
overall EGFR alteration in 45% of GBMs (TCGA, 2008). All cases with amplification 
of EGFR also show EGFR overexpression, and 70-90% of GBMs with EGFR over-
expression has EGFR gene amplification (Biernat et al., 2004). The most frequent 
mutant form of the EGFR is variant 3 (EGFRvIII) with deletion of exons 2 to 7. This 
mutation leads to a constantly active receptor independent of ligand and causes 
downstream mitogenic effects (Gan et al., 2009). 
 
The PDGFRs are two other RTK receptors that have been found frequently deregulated 
in GBM. The PDGF family is composed of four ligands, PDGF A, B, C and D, and two 
receptors, PDGFRα and β. All PDGF ligands and receptors have been found expressed 
in glial tumors (Lokker et al., 2002; Nister et al., 1982; Nister et al., 1988), suggesting 
autocrine and paracrine loops stimulating glioma growth (Hermanson et al., 1992). 
PDGFR deregulation occurs in all grades of glioma (Fleming et al., 1992; Hermanson 
et al., 1996) and more commonly in secondary GBM compared to primary GBM. 
Essentially, the PDGFRα is expressed on tumor cells, while the PDGFRβ is expressed 
on tumor vessels.  Recent TCGA data confirmed that around 13% of GBMs have 
PDGFRA gene amplification (TCGA, 2008).  
 
The phosphatidylinositol 3-kinase (PI3K) complex is composed of a catalytic protein 
encoded by PIK3CA and a regulatory protein encoded by PIK3R1. PI3K 
phosphorylates phosphatidylinositol-4, 5-bisphosphate (PIP2) to PIP3, that activates 
downstream molecules AKT/PKB (protein kinase B) and the mammalian target of 
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rapamycin (mTOR), which further stimulates cell growth and proliferation and inhibits 
apoptosis. Mutations both in the catalytic domain and the regulatory domain of PI3K 
have been found in glioma. Mutated PIK3CA was found in 15% of GBM (Samuels et 
al., 2004) and mutated PIK3R1 presents in 10% of GBM (TCGA, 2008). In 
physiological situations, the PIP3 level is kept relatively low by phosphatases, notably 
the phosphatase and tensin homolog (PTEN). Inactivation of PTEN would lead to up-
regulation of PIP3 and further hyper-activate the PI3K downstream pathway. Indeed, 
PTEN is frequently mutated in primary GBM (36%), but rarely in secondary GBM 
(Knobbe et al., 2002; TCGA, 2008). Thus, this suggests two ways by which the PI3K 
pathway can become de-regulated in GBM, by hyper-activation of PI3K and 
inactivation of PTEN. 
 
A RAS mutation is rarely found, in only 2% of GBM (TCGA, 2008). RAS is normally 
activated by RTKs and stimulates the downstream MAPK pathway. Neurofibromin-1 
(NF1), a negative regulator of RAS, was recently found to be mutated and deleted in 
18% of GBMs, and is recently regarded as a human GBM suppressor gene (TCGA, 
2008). 
 
1.2.3.3 Deregulation of the cell cycle in glioma 
 
TP53 is a tumor suppressor gene, widely mutated and/or deleted in about 50% of 
human cancer (Hollstein et al., 1991). p53, referred  to as the “guardian of the genome”, 
plays crucial roles in cell cycle arrest, apoptosis, senescence and differentiation in 
response to cell stresses such as hypoxia, DNA damage and oncogenic signaling 
(Vousden and Lane, 2007). The p53 level in cells is controlled by two critical 
regulators, MDM2 and p14ARF. MDM2 binds to p53 and blocks the ability of p53 to 
act as a transcription factor and degrades the protein, while ARF acts as an MDM2 
antagonist and increases p53 levels (Soussi and Wiman, 2007). Once a cell has lost 
ARF activity to block MDM2 function, MDM2 will promote p53 degradation without 
control. P53 mutations are common in low-grade astrocytoma (Ohgaki and Kleihues, 
2007) and were reported more frequent in secondary GBM than in primary GBM 
(Ohgaki et al., 2004; Ohgaki and Kleihues, 2005). Recent TCGA studies have 
demonstrated that P53 mutations and deletions are present in 35% of GBMs, 
amplification of MDM2 in 14% of GBMs and mutations or deletions of p14ARF in 
49% of GBMs. The overall frequency of p53/MDM2/p14ARF pathway deregulation in 
GBM was found to be 87% (TCGA, 2008). MDM2 gene amplification occurs 
exclusively in those primary GMBs that lack a p53 mutation (Biernat et al., 1997; 
Reifenberger et al., 1993).	  
 
The master governor of the cell cycle clock is retinoblastoma protein (RB). The 
p16INK4a/CDK4/RB pathway regulates the G1 to S phase transit in the cell cycle. The 
CDK/cyclin D1 complex phosphorylates RB, hyperphosphorylated RB releases the 
E2F transcription factor that activates the genes involved in G1/S transition. P16INK4a 
inhibits the CDK/cyclin D1 complex, thereby inducing hypophosphorylated RB which 
binds to E2Fs, thus inhibiting the G1/S transition. TCGA has shown that mutations or 
homozygous deletions in GBM for RB and p16INK4a genes was 11% and 52% 
respectively, amplification of CDK4 and CCND2 was 18% and 2%, respectively. The 
overall frequency of alteration of the p16INK4a/CDK4/RB pathway was 78% (TCGA, 
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2008), including primary and secondary GBM. Deregulation of the 
p16INK4a/CDK4/RB pathway was also frequent (65%) in anaplastic 
oligodendroglioma, but rare (4%) in oliogdendroglioma (Watanabe et al., 2001). 
 
1.2.3.4 IDH1 mutation 
 
Isocitrate dehydrogenases (IDHs) are a group of enzymes involved in multiple 
metabolic processes and protect cells from oxidative stress (Weller et al., 2011). There 
are three IDH variants in humans. IDH1 is present in the cytosol, while IDH2 and 
IDH3 are located in mitochondria. Only IDH1 and IDH2 mutations are known to be 
involved in human cancer. IDH1 mutations impair the enzyme’s affinity for its 
substrate and inhibit normal IDH1 activity (Yan et al., 2009). 
 
IDH1 mutations were first identified by a comprehensive genomic analysis of human 
GBM (Parsons et al., 2008). Mutations in the active site of IDH1 were found in 12% of 
GBM patients. Follow-up studies have shown that IDH1 mutations are frequent (>80%) 
in diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic 
oligodendroglioma, oligoastrocytoma and secondary GBM (Balss et al., 2008; 
Watanabe et al., 2009). IDH1 mutations are associated with younger age, secondary 
GBM and an increase in overall survival. The most common mutation found in IDH1 is 
the R132H mutation. On the other hand, IDH1 mutations are rare (<5%) or even absent 
in pilocytic astrocytoma and primary GBM. IDH1 mutations could not be found in 
ependymoma or other tumors in or outside of the CNS (Yan et al., 2009).  
 
The high mutation frequency in low-grade glioma and secondary GBM suggests IDH1 
mutation could be adopted as a useful diagnostic mark to distinguish different types of 
low-grade gliomas. The majority of low-grade diffuse astrocytomas carry p53 and 
IDH1 mutations, while the majority of oligodendrogliomas have IDH1 mutation plus 
1p/19q loss (Watanabe et al., 2009). Therefore, the molecular classification of glioma 
by analysis for IDH1 mutation, p53 mutation and 1p/19q loss is becoming more and 
more accepted in clinical pathology. 
 
 
1.2.4 Epigenetic alterations in glioma 
Epigenetic changes such as histone modifications and DNA hyper-/hypo-methylation 
changes are known hallmarks of human cancer. The cancer-specific DNA methylation 
changes include global DNA hypomethylation and gene-specific promoter 
hypermethylation (Jones and Baylin, 2007) as well as differential methylation of CpG 
island shores (Irizarry et al., 2009). Global DNA hypomethylation correlates with 
chromosomal instability (Eden et al., 2003), while promoter CpG islands 
hypermethylation generally results in transcriptional silencing of the respective genes. 
Gene-specific promoter hypermethylation has been widely shown to serve as a 
biomarker for prognosis and prediction of therapy responses (Laird, 2003) in different 
types of cancer including GBMs and other subtypes of gliomas (Nagarajan and 
Costello, 2009; Uhlmann et al., 2003). Histone modifications such as changes in 
histone acetylation and methylation have also been implicated in tumorigenesis (Baylin 
and Jones, 2011). 
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1.2.4.1 Global DNA hypomethylation in GBM 
 
Genome-wide reduction in 5-methylcytosine, global DNA hypomethylation, has been 
documented in many different malignancies compared with matching normal tissues 
(Ehrlich, 2002; Feinberg and Tycko, 2004) and is associated with the degree of tumor 
aggressiveness in a mouse skin cancer model (Fraga et al., 2004). In primary GBM, 
global hypomethylation occurs at a high frequency (80%), but the level of 
hypomethylation varies between GBM samples. The more severe the global 
hypomethylation, the more proliferative is the GBM (Cadieux et al., 2006). 
 
The mechanism by which global DNA hypomethylation contributes to tumorigenesis 
could be through oncogene activation and promotion of chromosome instability 
(Cadieux et al., 2006). The induced global DNA hypomethylation by loss of DNA 
methyltransferase 1 (DNMT1) function resulted in increased genomic instability and 
thus accelerated tumor incidence in a mouse sarcoma model (Eden et al., 2003). The 
molecular consequences of global DNA hypomethylation in GMB are not yet 
understood. 
 
1.2.4.2 Gene specific promoter DNA hypermethylation in GBM 
 
Gene-specific DNA hypermethylation mostly occurs at CpG islands of gene promoters. 
CpG islands (500bp-1kb) are regions with more than 5 times more abundant CpG 
nucleotides than the rest of the genome. Genes such as TP53, PTEN, RB, CDKN2 that 
are responsible for cell cycle control and apoptosis have been reported with promoter 
hypermethylation in many types of tumors including gliomas (Amatya et al., 2005; 
Baeza et al., 2003; Bello and Rey, 2006; Costello et al., 1996; Nakamura et al., 2001). 
A study has also shown that in GBM, transforming growth factor β (TGFβ) promotes 
cell proliferation through the epigenetic regulation of the PDGFB gene promoter 
(Bruna et al., 2007). It has also been shown that secondary GBM has a higher 
frequency of promoter hypermethylation than primary GBM (Ohgaki and Kleihues, 
2007). 
 
1.2.4.3 Silencing of the MGMT gene 
 
Gene-specific promoter hypermethylation can affect the sensitivity of GBM patients to 
chemo- and radiotherapy. The best example of this is O6-methylguanine-DNA 
methyltransferase (MGMT) promoter methylation. 
 
MGMT is a DNA repair enzyme that is associated with resistance to alkylating agents 
used in cancer therapy. MGMT removes alkyl groups from the O6 position of guanine. 
Cells without MGMT allow accumulation of O6-alkylguanine in DNA, which triggers 
mismatch repair and induces DNA damage (Weller et al., 2010). Hypermethylation of 
the MGMT gene promoter, leading to transcriptional silencing of the gene, occurs in 
multiple human tumors including glioma (Esteller et al., 1999). GBM patients with 
MGMT promoter methylation show sensitivity to alkylating agents such as 
temozolomide, and the methylation status also predicts better prognosis (Hegi et al., 
2005). MGMT promoter methylation has now been established as an independent 
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prognostic marker for GBM patients receiving chemotherapy and radiotherapy (Stupp 
et al., 2009). 
 
1.2.4.4 CpG methylator phenotype in glioma 
 
DNA hypermethylation in gene promoter regions is regarded as a common feature of 
cancer. The global pattern of CpG island hypermethylation in human cancer has been 
described as the CpG island methylator phenotype (CIMP). Cancers with the CIMP+ 
phenotype represent a distinct group with distinct clinical and molecular features (Issa, 
2004). 
 
The first CIMP phenotype was found in colorectal cancer (Toyota et al., 1999), and 
subsequent studies also confirmed CIMPs in other types of cancer (Issa, 2004). 
Recently, studies on the large collection of GBM samples through TCGA have 
demonstrated the existence of a glioma CIMP (G-CIMP) subgroup of GBMs 
(Noushmehr et al., 2010). Furthermore, it was found that the G-CIMP glioma is more 
prevalent among low-grade gliomas than among high-grade and is tightly associated 
with IDH1 mutations. Patients with the G-CIMP phenotype are usually diagnosed at a 
younger age and display significantly improved outcome. Thus, G-CIMP represents a 
distinct subgroup of human gliomas based on the molecular and clinical characteristics. 
 
1.2.4.5 Histone modification changes in glioma 
 
Histones and DNA comprise the nucleosome, the basic unit of chromatin. The N-
terminal tails of histones can be post-translationally modified, by methylation, 
acetylation and other types of modifications. The histone modification status influences 
the overall chromatin structure, further having positive or negative effects on gene 
transcription.  Histone acetylation, for example, is usually associated with active gene 
transcription, while histone methylation could be either activating or repressing gene 
expression depending on the specific methylation site (Baylin and Jones, 2011). All 
these histone modifications are governed by a series of enzymes such as histone 
methyltransferases, demethylases, acetyltransferases, deacetylases (HDAC) etc. 
 
Several studies have shown aberrant HDAC expression and histone modification 
patterns in gliomas and other types of brain tumors (Campos et al., 2011; Liu et al., 
2010; Lucio-Eterovic et al., 2008). Whole genome sequencing revealed that histone-
lysine N-methyltransferase genes and the H3F3A gene which encodes histone H3.3 are 
mutated in childhood glioblastoma and medulloblastoma (Schwartzentruber et al., 
2012; Wu et al., 2012). Further, amplification and deletion in genes regulating histone3 
lysine9 (H3K9) methylation were identified in medulloblastoma, implying that 
defective control of the histone code contributes to the pathogenesis of 
medulloblastoma (Northcott et al., 2009). 
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1.2.4.6 IDH1 mutation and the altered epigenome of glioma 
 
IDH1 mutations have been identified in about 75% of low grade gliomas and secondary 
GBM (Yan H, 2009 N Engl J Med), and are increasingly recognized as valuable 
diagnostic and prognostic markers for gliomas. 
 
Normally IDH1 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate 
(α-KG). IDH1 mutations, however, lead to reduced IDH1 activities, resulting in 
decreased α-KG and α-KG-dependent prolyl hydroxylase (PHD) activity and further to 
an increase in HIF-1α, a PHD substrate (Zhao et al., 2009).  
 
In addition, the mutant IDH1 gains the function to catalyse the α-KG to 2-
hydroxyglutarate (2-HG), resulting in accumulation of 2-HG in gliomas. 2-HG is an 
antagonist of α-KG. It competitively inhibits the α-KG-dependent dioxygenases, 
including histone demethylases and the ten-eleven translocated (TET) family of 
oxidizing enzymes, leading to increase of histone methylation and decrease of the 5-
hydroxymethylcytosine (5-hmC) level in gliomas (Xu et al., 2011). 5-hmC is generated 
by conversion from 5-mC by the TET family of oxidizing enzymes, and has been 
identified as an epigenetic phenomenon occurring during embryonic stem cell 
differentiation and human cancer (Haffner et al., 2011; Jin et al., 2011; Koh et al., 
2011). Therefore, the tumor-derived IDH1 mutations alter the DNA methylation pattern 
and impair histone demethylation, further blocking the differentiation of non-
transformed cells (Lu et al., 2012). 
 
 
1.2.5 Molecular sub-classification of glioma 
The current suggested molecular sub-classification of gliomas is based on 
transcriptional signatures. These gene expression signatures combined with DNA 
sequence, gene copy number and methylation data provide rich information concerning 
the underlying patterns of signaling aberrations, which in turn can be used to predict the 
clinical prognosis for individual patients.  
 
In recent years, the existence of several subtypes of GBM has been proposed based on 
their transcription signatures. Two of the studies in particular have received a lot of 
attention (Phillips et al., 2006; TCGA, 2008).  
 
In 2006, Philips et al., first reported on the identification of three prognostic subgroups 
of GBM samples, named Proneural, Proliferative and Mesenchymal. The Proneural 
subgroup expresses genes associated with neurogenesis and has a better prognosis, 
while the Proliferative and Mesenchymal subgroups are characterized by markers of 
cell proliferation and mesenchymal phenotype respectively, both with poor prognosis. 
The Proliferative subgroup has an increased MIB-1 labeling index, whereas the 
Mesenchymal subgroup shows increased angiogenesis. 
 
More recently, gene expression data from TCGA suggested four transcriptional subsets: 
Proneural, Mesenchymal, Classical and Neural, three of those are further connected 
with distinct patterns of genetic alterations (Verhaak et al., 2010). The Proneural subset 
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includes samples with amplification of PDGFRA, IDH1 mutations and TP53 
loss/mutation; The Mesenchymal subset is associated with loss/mutation of NF1, TP53 
and CDKN2A (INK4a/ARF); The Classical subset has EGFR amplification and 
deletion of PTEN, p16. The fourth subset, the Neural subset, shows a diversified 
genotype and has characteristics in common with normal neural developmental 
lineages. 
 
The proposed sub-classification of gliomas by Philips et al. and the TCGA was based 
on different sample sets and different methodologies. Both have their prognostic and 
predictive values. The concordance of the two classification sets is the Proneural and 
Mesenchymal subgroups, which reflects the robustness of the Proneural and 
Mesenchymal signatures in GBM (Huse et al., 2011). Transcriptional signature sub-
classification has not been widely applied in clinics. This could be due to the lack of 
consensus on the exact nature of the subgroups and also to the lack of effective therapy 
for any specific subtype (Huse et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Molecular sub-classification of glioma [copied with permission from   
(Brennan, 2011)] 
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1.3 MOUSE MODELS FOR GLIOMA RESEARCH 
Experimental mouse models are widely used in cancer research as a useful system to 
understand basic tumor biology and develop new approaches to conquer cancer. 
Basically, these in vivo mouse model systems fall into two categories: implanting 
human tumor cells into mice and creating tumors in mice de novo. 
 
 
1.3.1 Implantation models 
In the implantation model, tumor cells can be injected back to the same species 
(allografts) or implanted to a different species (xenografts). Xenograft models can also 
use orthotopic xenografts (in the original site) or heterotopic xenografts (in a site 
different from the original tumor location, often subcutaneously) in immunodeficient 
mice. Orthotopic xenograft GBM models have been used in many studies concerning 
GBM cancer stem cells and their microenvironment (Inda et al., 2010; Singh et al., 
2003; Singh et al., 2004). It has been shown that tumors induced from orthotopic 
injections with the cells freshly isolated from patient samples propagated in conditioned 
media without serum but with growth factors were more close to the phenotype and 
genotype of the primary tumors when compared with the tumors generated from cells 
maintained in regular serum containing media (Lee et al., 2006). 
 
There are some drawbacks with xenograft models. Most of the intracranial injections 
are done in immunocompromised mice, thus this in vivo assay will neglect the 
importance of immune surveillance in tumor development. In addition, the tumor 
initiation process in xenograft models differs considerably from spontaneous tumor 
development. 
 
However, brain tumors generated from implanted tumor cells are highly reproducible, 
some with high growth rate. Serial transplantation of brain tumor cells in vivo has been 
taken as a golden standard for the functional definition of brain tumor stem cells 
(BTSCs) in GBM (Vescovi et al., 2006) and yields valuable information regarding 
cancer stem cell biology in GBM. 
 
 
1.3.2 Genetically engineered mouse models of brain tumors 
Another approach to modeling brain tumors in animals is to use genetically engineered 
mouse models (GEMMs), which mimic genetic changes in patients.  
 
GEMMs can be generated by germline modifications, such as by transgenic techniques 
(gain of function) and gene targeting (loss of function). Transgenic mouse models of 
glioma usually use a cell type-specific promoter to drive expression of an oncogene. 
The cDNA of the gene of interest, which is introduced into an expression vector under 
the GFAP or Nestin promoter, is microinjected into a fertilized oocyte and 
subsequently randomly incorporated into the host genome. Gene targeting, on the other 
hand, is using homologous recombination technique to manipulate the gene of interest, 
by “knock-in” or “knock-out”. With the development of the Cre-loxP system, 
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conditional deletion of a gene of interest can be made tissue-specific. By cross-breeding 
the transgenic and gene-targeted mouse strains, the co-operative effects of oncogenes 
and tumor suppressor genes can be determined. Many transgenic or gene targeting 
malignant glioma mouse models have been generated and have provided exciting 
results (Ding et al., 2001; Reilly et al., 2000; Wang et al., 2009; Zhu et al., 2005). 
 
GEMMs can also be achieved with somatic cell gene transfer techniques by using 
retroviral transduction. One technique uses the replication competent Moloney Murine 
Leukemia Virus (MMLV) in combination with the wild-type MMLV helper virus to 
deliver the targeted gene to proliferating cells in newborn mouse brains. However, the 
origin of the infected cell is unknown (Uhrbom et al., 1998). Another approach is using 
an avian leucosis virus (ALV)-derived replication competent virus (RCAS) together 
with its receptor tumor virus-A (tv-a) to transfer genes to selected cell types. Normal 
mammalian cells do not express the tv-a receptor. Transgenic tv-a mice have been 
designed to be controlled by different cell type-specific promoters such as the Gfap or 
Nestin promoter. By injection of RCAS virus with the gene of interest to the tv-a 
mouse brain, the RCAS infection will be restricted to tv-a expressing cells (Holland et 
al., 1998; Holland and Varmus, 1998). The RCAS-tva model could also be combined 
with the Cre-loxP system or gene knock out mouse lines to allow postnatal over 
expression of oncogenes and/or deletion of tumor suppresser genes in a cell type-
specific manner (Hu et al., 2005; Uhrbom et al., 2002). 
 
Recently, using other viral transduction systems like adenoviral (Alcantara Llaguno et 
al., 2009; Zhu et al., 2009) and lentiviral vectors (Marumoto et al., 2009) combined 
with the Cre-loxP system to express the genes of interest, more region- and cell type- 
specific glioma mouse models could be established (Marumoto et al., 2009). 
 
 
 
1.4 BRAIN TUMOR STEM CELLS – POSSIBLE TARGETS FOR GLIOMA 
THERAPY 
 
1.4.1 Brain tumor stem cells 
Many brain tumors, especially GBMs, are heterogeneous. They often contain 
undifferentiated cells as well as differentiated cells. Putative BTSC, CSCs in brain 
tumors, might be responsible for tumor initiation, formation and maintenance of 
heterogeneity of the tumor. 
 
1.4.1.1 Identification of BTSCs in brain tumors 
 
The BTSCs in brain tumors were first identified based on the neurosphere assay that 
was adopted from the studies on NSCs. Isolated brain tumor cells were cultured in 
serum free media, in the presence of EGF and bFGF growth factors, forming floating 
spheres from single cells (Galli et al., 2004; Hemmati et al., 2003; Singh et al., 2004). 
These tumor sphere cells express NSC/progenitor cell markers such as CD133, SSEA1, 
Nestin, Sox2, BMI1 and Musashi (Dahlstrand et al., 1992; Favaro et al., 2009; Strojnik 
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et al., 2007), but not differentiated neural cell markers. They can be partially 
differentiated to neuronal and glial cell lineages in the presence of serum.  
 
Subsequent studies used CD133 (Prominin 1) as a marker to isolate BTSCs from 
GBMs (Galli et al., 2004; Singh et al., 2004). It was found that only the fractions of 
CD133+ cells could give rise to tumor xenografts in mice. However, these results have 
been challenged by other studies showing that also CD133- cells can be tumorigenic 
(Beier et al., 2007; Wang et al., 2008). Several groups reported that only around 60% of 
primary GBM samples contain CD133+ cells, meaning that CD133 may not be a 
universal enrichment marker for BTSCs (Beier et al., 2007; Joo et al., 2008; Ogden et 
al., 2008). In search of an alternative marker, stage-specific embryonic antigen-1 
(SSEA1) was proposed as a more general enrichment marker for BTSCs in GBM after 
demonstrating that SSEA1+ cells fulfilled the criteria for BTSCs and were present in 
almost all tumor samples analyzed (Son et al., 2009).  
 
1.4.1.2 Cell of origin of BTSCs 
 
The cell-of-origin of BTSCs is a matter of debate although there is accumulating 
evidence for the existence of BTSCs in brain tumors. BTSCs are defined as such 
because they share some properties with adult neural stem cells in the brain and have 
self-renewal and in vivo tumorigenic properties. Nevertheless, NSCs are attractive 
candidates as the cell-of-origin of BTSCs. NSCs are slowly dividing cells and have a 
long life span, which probably allow them to accumulate enough mutations during the 
life time of an individual for neoplastic transformation to occur (Chen et al., 2012). 
There is a considerable similarity between NSCs and BTSCs in terms of the signaling 
pathways, cell surface markers, invasive ability and self-renewal capacity (Varghese et 
al., 2008).  
 
Many human malignant gliomas locate very close to the lateral ventricles (Barami et 
al., 2009), which supports the idea that the SVZ is a sensitive site for tumorigenesis. 
However, there are also many tumors arising in locations distant to the SVZ (Behin et 
al., 2003). This could be explained by the asymmetric division of BTSCs into two non-
identical daughter cells, where one may remain in the SVZ, and the other may migrate 
to a distant site and form a tumor mass there (Vescovi et al., 2006).  
 
The use of animal models has greatly facilitated cell-of-origin studies. Increased 
proliferative activities of neurospheres from p53-/- mice suggested an expansion 
capacity of the NSC pool in the SVZ, making it more vulnerable to malignant 
transformation (Gil-Perotin et al., 2006; Meletis et al., 2006). Further studies showed 
that exogenously added PDGF could induce aberrant proliferation of PDGFRα+ SVZ 
cells to form hyperplastic but reversible lesions with glioma features (Jackson et al., 
2006). Furthermore, direct introduction of initiating mutations into specific cell types 
using different promoters active during embryonic or early postnatal stage, such as 
Gfap and Nestin promoters, results in obvious glioma formation (Holland et al., 2000; 
Zheng et al., 2008; Zhu et al., 2005). Conditional deletion of Nf1 in the Gfap+ cell 
compartment on a p53 null background leads to 100% penetration of GBM in mice. 
Interestingly, early neoplastic changes were observed in the SVZ before tumors 
appeared, implying that transformed cells come from Gfap+ stem cells/progenitors in 
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the SVZ (Zhu et al., 2005). Recently, by using a stereotactic viral delivery method, it 
was possible to specifically target adult NSCs to address their capacity to initiate 
glioma formation. Malignant glioma formation was observed upon introduction of Nf1, 
p53 and/or Pten tumor suppressor mutations in neural stem/progenitor cells through a 
tamoxifen-inducible Nestin-driven Cre transgene (Alcantara Llaguno et al., 2009). 
Moreover, stereotactic delivery of Cre-expressing virus into the SVZ of adult mice with 
different combinations of mutated tumor suppressor genes such as Rb/p53/Pten results 
in tumor development. Interestingly, when virus was transduced into more 
differentiated brain regions such as the cerebral cortex, no tumors formed (Jacques et 
al., 2010). These data suggested that malignant gliomas more likely originate from 
neural stem/progenitor cells rather than from differentiated cells. 
 
Although an increasing amount of evidence show that SVZ neural stem/progenitor cells 
are the most likely cell-of-origin of many malignant gliomas, the possibility that de-
differentiation of mature glial cells generates more immature stem-like cells or 
restricted progenitor cells serving as the origin can not be excluded. More differentiated 
brain cells can acquire not only stem-like features but also the capacity to induce tumor 
formation (Zaidi et al., 2009). In a recent MADM (Mosaic analysis with double 
markers) mouse model, it was shown that malignant transformation only occurred in 
the oligodendrocyte precursor cells (OPCs) when p53 and NF1 were homozygously 
mutated in NSCs (Liu et al., 2011).  
 
1.4.1.3 The microenvironment of BTSCs 
 
One of the hallmarks of malignant behavior of glioma is the microvascular 
proliferation, providing nutrition to the tumor and contributing to tumor progression 
and invasion. Just like the normal stem cell compartment, the distribution of the 
putative BTSCs in the tumor mass is not random. It has been shown that BTSCs are 
often located in a special environment called the tumor perivascular niche, a 
microvascular proliferation zone that mimics the normal NSC niche (Calabrese et al., 
2007; Charles et al., 2010).  
 
The brain tumor perivascular niche is heterogeneous. It may be composed of different 
cell types including astrocytes, endothelial cells, pericytes, fibroblasts, microglia, 
differentiated tumor cells and BTSCs. The BTSCs secrete high levels of vascular 
endothelial growth factor (VEGF) to build up a surrounding microvasculature (Bao et 
al., 2006). Endothelial cells closely interact with BTSCs and secrete factors maintaining 
BTSCs properties (Calabrese et al., 2007). One of the endothelial cell-derived factors 
could be nitric oxide (NO) (Charles et al., 2010). In a PDGF-induced mouse glioma 
model, NO secreted by endothelial cells promoted stem cell like characteristics in cells 
present in the perivascular niche, enhancing this neurosphere forming capacity in 
primary cultures and their in vivo tumorigenic capability. This effect was mediated 
through the cGMP-dependent protein kinase (PKG) (cGMP/PKG) and the Notch 
pathway. When tumors grow and invade the surrounding tissues, they usually recruit 
external vessels for blood supply. More recently, two groups simultaneously found that 
BTSCs could give rise to endothelial cells that line the tumor vasculature (Ricci-Vitiani 
et al., 2010; Wang et al., 2010). Moreover, the tumor-derived endothelial cells were 
found to lack VEGF receptors and were therefore resistant to anti-VEGF therapy of  the 
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experimental GBM tumors (Sodaa Y and Sandra Pastorinod, 2011). These findings 
describe a new cross talk between BTSCs and endothelium in the perivascular niche, a 
new way of tumor vascularization, and a potential mechanism of resistance to anti-
VEGF therapy in GBM, and provide significant implications for future strategic 
therapy of GBMs. 
 
Oxygen is also a critical component of the perivascular niche in brain tumors 
(Mohyeldin et al., 2010). Oxygen tension is strictly regulated in physiological 
situations. Hypoxia (low oxygen tension) is important in maintaining stem cells in an 
undifferentiated state. Hypoxia maintains the self-renewal capacity of ES cells and 
prevents NSCs from differentiating (Clarke and van der Kooy, 2009; Simon and Keith, 
2008). Apart from the microvascular proliferation, pseudopallisading necrosis is 
another major feature of GBM, which is promoted by hypoxia. This hypoxic necrotic 
region within the tumor, usually located distal from the vasculature, is due to a rapid 
growth of the tumor mass and lack of an adequate vascular supply. Recently, hypoxia 
was proposed to define a secondary niche for BTSCs (Li et al., 2009; Seidel et al., 
2010). The BTSCs in the hypoxic niche were found to be mainly regulated by HIF-2α. 
Targeting the HIF-2α pathway inhibited BTSCs self-renewal, proliferation and survival 
in vitro and decreased tumorigenic potential in vivo. 
 
Interestingly, both hypoxia and NO from the perivascular niche not only affect cancer 
stem cell self-renewal and tumor growth, but was also shown to reprogram non-stem 
cancer cells towards a stem-like phenotype (Charles et al., 2010; Li et al., 2009), 
suggesting that tumor cells have a higher degree of plasticity compared to normal tissue 
cells. Tumor cells can dramatically change their phenotype depending on the 
microenvironment. Therefore, tumor targeting may not only focus on cancer stem cells, 
but the BTSC niche and the non-BTSC cancer cells should be targeted as well. 
 
1.4.1.4 Epigenetic origin of BTSCs 
 
Given the idea that CSCs give rise to other differentiated non-CSCs within the tumor, 
this type of cellular heterogeneity of tumors might be initiated by epigenetic 
reprogramming (Vincent and Van Seuningen, 2012). It would, for example, be 
interesting to compare the epigenetic profile between CSCs and non-CSCs to see if 
differences exist. There are some initial reports showing disturbed level of DNA 
methylation and H3K27me3 repressive histone marks in putative breast CSCs 
compared to their non-CSCs (Yasuda et al., 2010). Also, a genome-scale histone 
reprogramming profile during epithelial-to-mesenchymal transition (EMT) was 
recently presented (McDonald et al., 2011). A research goal of many groups is to 
discriminate tumorigenic CSCs from their differentiated non-tumorigenic counterparts 
based on their epigenetic landscapes, so that the epigenetic modifications of CSCs 
could be taken as potential targets for therapy. 
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1.4.2 Treatment of glioblastoma 
1.4.2.1 Conventional treatment 
 
Standard treatment for newly diagnosed malignant glioma is surgery plus radiotherapy 
and chemotherapy. Surgical resection is the first line of treatment. However, due to the 
infiltrative nature of GBM, residual tumor cells usually remain. The addition of 
radiotherapy can increase survival of GBM patients from 3-4 months to 7-12 months 
(Stupp et al., 2005). Unfortunately, after standard radiotherapy, 90% of the tumors 
recur at the original site (Wen and Kesari, 2008). Chemotherapy is now playing an 
increasingly important role in the treatment of GBMs. The combination of radiotherapy 
and temozolomide improves the median survival by 2.5 months compared with 
radiotherapy alone (Stupp et al., 2009). Current temozolomide-based 
radiochemotherapy has become the standard treatment (Stupp and Weller, 2010). For 
the recurrent GBM, Bevacizumab, a monoclonal antibody neutralizing VEGF, is 
widely used in clinical settings, regrettably the clinical responses are merely transient 
(Mellinghoff et al., 2011). Despite optimal treatment and some beneficial effect of 
systematic combination of temozolomide and radiotherapy, the median survival is 
around 15 months for GBM patients (Asklund T, 2012). 
 
1.4.2.2 Targeted therapy of GBM 
 
A better understanding of the molecular changes involved in the development of 
malignant glioma provides better chances to develop more effective personalized 
targeted therapy for patients. Relevant growth factor pathways in malignant gliomas 
include EGF, PDGF, VEGF and insulin-like growth factor (IGF). Targeting ligands and 
receptors in these signaling pathways would hopefully increase efficacy and minimize 
toxicity, provided individual patient’s tumor could be analyzed before choices of 
treatment and the substances could be designed to reach their targets in the brain. Low 
molecular weight-tyrosine kinase inhibitors (LMW-TKI) and monoclonal antibodies 
are two types of agents being developed for glioma targeted therapy. 
 
Approximately half of GBMs have EGFR gene amplification, often accompanied by 
overexpression of the EGFRvIII mutant. Two kinase inhibitors of EGFR, erlotinib and 
gefitinib have been used in clinical trials. Disappointingly, there was no significant 
effect on overall survival or progression-free survival at 6 months in GBM patients 
(Mellinghoff et al., 2011; Sathornsumetee and Rich, 2008). Drug response and tumor 
genotype are usually closely related. One reason for the trial failure might be that the 
trial was not conducted on a molecularly defined patient population. Another 
explanation could be that GBMs have co-activation of multiple tyrosine kinases and 
redundant signaling pathways. A single EGFR inhibitor might thus not have enough 
activity. 
 
PDGF signaling is also critical for glioma development. Imatinib (Gleevec), a PDGFR 
inhibitor, has failed to show effects in some phase I/II clinical trials (Wen et al., 2006). 
However, a combination of Imatinib and hydroxyurea has demonstrated promising but 
not statistically significant effects in patients (Dresemann, 2005; Reardon et al., 2005). 
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The rich vasculature within GBMs presents attractive targets of angiogenesis inhibitors 
(Norden et al., 2009). VEGF is a key regulator of tumor angiogenesis. Targeting the 
VEGF pathway has become one focus of malignant glioma treatment. Bevacizumab 
(Avastin), a monoclonal antibody towards VEGF, is the first FDA approved 
antiangiogenic agent in cancer treatment. Bevacizumab may reduce tumor vascularity, 
and increase the uptake of chemotherapeutic agents (Sathornsumetee and Rich, 2008), 
but may facilitate tumor cell invasion (Keunen et al., 2011). In the clinical setting, 
Bevacizumab may not affect overall survival, but controls peritumoral edema and 
prolongs progression-free survival (Norden et al., 2009). Therefore, there is still a big 
challenge in finding a better way of targeting the VEGF pathway and the vasculature 
for therapy in GBM. 
 
1.4.2.3 Clinical implications and complexity of BTSCs in glioma treatment 
 
The identification of BTSCs in glioma presents a new insight to treatment. The BTSCs 
could survive through conventional chemo- and radiotherapy and initiate recurrence. 
Targeting BTSCs represents a platform for discovering new strategies to treat GBM 
patients.  
 
Therapeutic strategies to target BTSCs could for example be: targeting BTSC-
dependable signaling pathways (Bar et al., 2007); differentiating BTSCs to more 
committed cells losing their capacity to self-renewal and to give rise to other tumor 
cells by using bone morphogenetic protein (BMP) (Piccirillo et al., 2006) or through 
epigenetic drugs, such as HDAC or DNMT inhibitors (Vincent and Van Seuningen, 
2012); destroying the perivascular niche for BTSCs (Norden et al., 2009); and 
immunotherapeutic targeting of BTSCs (Li et al., 2012).  
 
Although the CSC concept has relevance in some clinical settings, more complexities 
and challenges have been highlighted in the application of CSC targeting therapy. 
Recent research has shown that CSCs can be phenotypically very flexible both within 
tumors and between tumors and also non-CSCs can be reprogramed into CSCs under 
certain circumstances (Gupta et al., 2009).  Therefore, new treatment strategies should 
include both CSC targeted therapy and conventional chemotherapy destroying the 
tumor mass (target non-CSCs). 
 
 
  24 
2 AIM OF THE STUDY 
 
The general aim of this study was to characterize the stem cell-like features of glioma 
and to start to apply them for experimental cancer stem cell-targeting therapies. This 
was achieved by using both human glioma materials and an experimental mouse 
glioma model in the following ways. 
 
 
Ø Paper I: By analyzing gene expression signatures of high-grade human glioma 
cultures, we aimed to identify different subsets of glioblastoma stem cells and 
explore their sensitivities to tyrosine kinase inhibitors. 
 
Ø Paper II: By examining human glioma tissues of various malignancy grades for 
the expression of transcription factors normally controlling self-renewal and 
pluripotency of embryonic stem cells and neural stem cells, we investigated if 
these ESC and NSC key regulators also are present and may have similar 
functions in human gliomas. 
 
Ø Paper III: By utilizing a recently established mouse glioma model with 
overexpression of human PDGFB in astrocytic brain cells in combination with 
a p53 null background, we aimed to explore the epigenetic changes occurring in 
the tumor-prone mouse brain before overt tumor formation. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I:  
IDENTIFICATION OF A SOX2-DEPENDENT SUBSET OF TUMOR- AND 
SPHERE-FORMING GLIOBLASTOMA CELLS WITH A DISTINCT 
TYROSINE KINASE INHIBITOR SENSITIVITY PROFILE 
By analyzing the gene expression data of 11 high-grade glioma cultures for their 
sensitivities to the LMW-TKIs mono-treatments, imatinib and NVP-AEW541, we 
identified two subsets of glioma, designated type A and type B cultures.  
 
A significance analysis of microarrays (SAM) revealed that type B cultures had high 
expression of genes encoding extracellular matrix proteins, suggesting that the subset 
had mesenchymal features. Type A cultures were characterized by high expression of 
GFAP, an intermediate filament of normal SVZ neuroepithelial stem cells in mice, 
early glia progenitors, and astrocytes. Moreover, gene set enrichment analysis (GSEA) 
suggested that genes characterizing type A and type B cells were regulated by different 
mechanisms involving transcription factors and microRNAs.   
 
As there were not so many known markers of adult neuroepithelial stem cells and their 
progeny within the microarray data set, we performed on type A and type B cultures a 
quantitative PCR (qPCR) analysis to measure the expression of a set of 17 genes. The 
17 genes selected had been previously implicated as markers for neuroepithelial stem 
cells and their progeny. Results showed that 8 out of the 17 genes had a different 
expression pattern between type A and type B cultures. SOX2, chemokine C-X-C 
receptor 4 (CXCR4), excitatory amino acid transporter 1 (EAAT1), and GFAP were 
more highly expressed in type A cultures, whereas type B cultures showed higher 
expression of genes associated with microglial and perivascular cells [laminin gamma 1 
(LAMC1) and PDGFRB] and a gene associated with the oligodendrocyte lineage [2’, 
3’-cyclic nucleotide 3’ phosphodiesterase (CNP)]. Chemokine C-X-C motif ligand 12 
(CXCL12) was also more highly expressed in type B cultures. NESTIN and BMI1, two 
established neuroepithelial stem cell markers, however, showed no difference between 
the two culture types. 
 
Next, we investigated the cancer stem cell properties of these cultures by analyzing 
their tumorigenic potential in vivo and self-renewal capacities in vitro. Tumor tissue 
from the patients that was used to establish the original cultures was minced and 
subcutaneously xenografted in severe combined immunodeficiency (SCID) mice. All 8 
tissue preparations representing the type A cultures formed tumors. In contrast, tumor 
formation was only observed with 4 out of the 12 tumor tissue preparations 
representing type B cultures. In addition, we prepared xenografts from two cell cultures 
of each type. Both the type A cultures induced tumors, but not the type B cultures.  
 
The self-renewal capacity of the glioma cultures was examined using both a 
neurosphere assay and a limiting diluting assay. Results showed that type A cultures 
generally formed higher number of larger spheres and displayed increased self-renewal 
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capacity compared to the type B cultures. Thus, the stem cell features of type A were 
more pronounced than for the type B cultures with regard to tumor- and sphere-forming 
capacities. 
 
The qPCR analyses suggested that high GFAP and SOX2 expression were features of 
type A cultures, and this was confirmed by immunofluorescence staining. The presence 
of SOX2 in most of the type A cell cultures indicates a tissue stem/progenitor cell 
phenotype in the majority of these cells. By knocking down SOX2 expression using the 
siRNA technique, we further demonstrated that the sphere-forming phenotype and the 
defining gene expression signature of type A cultures was SOX2 dependent. 
 
Previous studies have shown that type A cultures have reduced sensitivities to mono-
treatment with two tyrosine-kinase inhibitors, imatinib, the PDGFR inhibitor and NVP-
AEW541, the IGF-1R inhibitor. Interestingly, when SOX2 expression was down-
regulated, the sensitivity of type A cultures to imatinib and to NVP-AEW541 
increased.  More excitingly, all three type A cultures tested displayed a significant 
growth inhibition when treated with a combination of imatinib and NVP-AEW541.  
 
Finally, the clinical relevance of the two cultures was investigated by analyzing and 
comparing the publicly available gene expression data sets generated from human 
glioblastoma samples. Results demonstrated that the type A- and type B-defining gene 
signatures were expressed in different sets of human glioblastoma rather than 
coexpressed in the same tumors. Classification of glioblastoma with type A- and type 
B-defining genes generated two groups of tumors composed of the 
proneural/classical/neural subsets and the mesenchymal subset, respectively. Moreover, 
tumors with EGFR mutations were enriched in the type A group. 
 
Taken together, we have identified a SOX2-dependent subset of tumor- and 
neurosphere-forming glioblastoma cultures characterized by a gene expression 
signature similar to that of recently described proneural/classical/neural subsets of 
glioblastoma. The findings that resistance to PDGF- and IGF-1-receptor inhibitors is 
related to SOX2 expression and can be overcome by combination treatment should be 
considered in ongoing efforts to develop novel stem cell-targeting therapies. 
 
 
 
3.2 PAPER II:  
ACTIVATION OF NEURAL AND PLURIPOTENT STEM CELL SIGNATURES 
CORRELATES WITH INCREASED MALIGNANCY IN HUMAN GLIOMA 
It has been suggested that mechanisms promoting the maintenance and self-renewal of 
stem cells have a similar function in glioma tumor cells. However, little is known about 
the expression pattern of these neural and pluripotency-associated transcriptional 
network proteins in gliomas, and if these proteins are important for glioma 
tumorigenesis. Furthermore, independently of genetic alterations, would these proteins 
constitute relevant targets for therapeutic strategies aiming to prevent growth and 
recurrence of the tumor? 
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Therefore, we examined human glioma tissues for the expression of transcription 
factors with key roles in controlling the self-renewing undifferentiated state of NSCs 
and ESCs, such as SoxB1 (Sox1, Sox2 and Sox3), Oct4, Nanog and Klf4.  
 
Previous studies have shown that SoxB1 genes are co-expressed by the majority of 
NSCs both in the developing and adult CNS, and constitute important regulators of 
NSC maintenance. By using in situ hybridization and immunofluorescence staining, we 
investigated expression at both the mRNA and protein level, and we found that 
undifferentiated proliferating cells in high grade gliomas co-express Sox1-3 
transcription factors which was similar to stem cells of a healthy CNS. Further, an in 
vitro gain-of-function assay demonstrated that as in the developing CNS, Sox3 has the 
capacity to maintain glioma cells in an undifferentiated and proliferating state, whereas 
active repression of Sox3 causes cells to exit the cell cycle. 
 
The expression of ESC regulatory genes in different grades of glioma was examined by 
qRT-PCR and immunostaining. Results showed that the combined expression of Sox2, 
Oct4, Nanog and Klf4 was associated to an increased malignancy grade of glioma. 
Moreover, an array of mesodermal and endodermal markers was used to analyze the 
glioma samples. It was found that apart from neural markers, many cells in grade IV 
tumors had activated gene expression representative of the mesodermal and 
endodermal cell developmental lineages, indicating that gene expression programs 
normally present in other than neural lineages are active in high-grade glioma. 
 
Finally, the influence of the microenvironment on the expression of stem cell properties 
was assayed by measuring the Sox2, Oct4 and Nanog protein level in primary 
glioblastoma cells after intracranial xenografting, serial subcutaneous transplantation 
and in vitro culturing. The resulting xenograft tumors from both intracranial 
transplantation and serial subcutaneous transplantation contained comparable amounts 
of Sox2, Oct4 and Nanog expressing cells as the original human tumors, whereas 
glioma cells cultured in vitro initially expressed high levels of Sox2, Oct4 and Nanog, 
but the expression of Oct4 and Nanog declined upon continuous propagation in vitro 
either as monolayer or as spheres. In contrast, Sox2 expression remained unaltered in 
cultures. These data suggested that while the NSC gene Sox2 remains unchanged in 
cultures, the expression of Oct4 and Nanog is dependent on extra-cellular regulatory 
cues present in vivo but not in vitro.  
 
In conclusion, this paper demonstrated a generally deregulated expression of neural and 
pluripotent stem cell gene signatures in human malignant gliomas, which might allow 
for the pluripotent features presented by glioblastoma cells. Independently of any 
genetic alterations, the stem cell regulatory program, when aberrantly present in tumor 
cells, may constitute a significant target for therapeutic strategies.  
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3.3 PAPER III:  
HISTONE3 LYSINE9 METHYLATION AND DNA HYPOMETHYLATION 
DURING THE PRE-NEOPLASTIC STAGE OF EXPERIMENTAL MOUSE 
GLIOMA  
As an alternative to the human tumors (used in the previous two papers), we used an 
established mouse glioma model to systematically study epigenetic alterations in mouse 
brain tumors and in the morphologically normal mouse brains before tumor formation. 
 
We have previously generated a transgenic mouse in which the human GFAP promoter 
directs expression of human PDGFB to mouse astrocyte and astrocyte 
progenitor/neural stem cells. This hGFAPpPDGFB (B+) mouse was then crossed on to 
a p53 null background, mimicking the genotype of human secondary GBM. These 
hGFAPpPDGFB/p53 null (B+p53-/-) mice do not develop visible brain tumors until 3-6 
months postnatally making it possible to follow the initial stages of tumor development 
in the mouse brain. In this study, we showed that histone3 lysine9 methylation 
(H3K9Me) and global DNA hypomethylation were present in mouse glioma samples 
and had occurred in the mouse neural stem/progenitor cells before tumor formation. 
 
We examined the epigenetic status of the mouse glioma including the global DNA 
methylation level and global histone3 methylation status by immunohistochemistry. 
We found a profound reduction of DNA methylation in brain tumor tissue compared to 
adjacent normal brain tissue as visualized by both 5-hydroxymethylcytosine (5-hmC) 
and 5-methylcytosine (5-mC) stainings. On the contrary, the H3K9Me2 level was 
increased in the tumor cells compared to normal brain cells. It was also interesting to 
see that the Ki67 positive, proliferating tumor cells were almost devoid of 5-hmC 
staining. 
 
NSCs are one of several cell types to be the putative origin of glioma. Do NSCs from 
the tumor permissive (B+p53-/-) brain exibit proliferative advantages and are they 
subject to epigenetic modifications before tumor formation? The sphere formation 
assay and the limiting dilution assay demonstrated a higher self-renewal capacity and 
proliferative advantage of NSCs from the tumor permissive B+p53-/- mouse brain than 
wild type (WT) NSCs. 
 
We also monitored the global DNA methylation levels in neurospheres by 5-mC and 5-
hmC immunostainings on cryosectioned spheres, by antibody based dot blot analysis 
and also by Luminometric Methylation Assay (LUMA), a methylation-sensitive 
restriction enzyme based assay followed by pyrosequencing. Although we could not 
demonstrate obvious global DNA methylation differences among neurospheres from 
four different genotypes of mice, there was a trend towards decreased DNA 
methylation in tumor spheres compared to neurospheres derived from the same            
B+p53-/- mouse. 
 
The DNA methylation status could be very much influenced by the in vitro and in vivo 
environment. Therefore, we analyzed the global DNA methylation status in mouse 
brain tissues. Previous analyses of clinical samples and mouse models provide evidence 
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pointing to the SVZ of the lateral ventricular wall (LVW) as a region of origin for 
malignant glioma. Therefore, we dissected out the LVW of different mouse brains and 
examined the global DNA methylation status of this particular region by LUMA assay. 
We found that the global DNA methylation level was significantly lower in the LVW 
from B+p53-/- mice compared to WT mice. There was a trend of Dnmt3a (de novo DNA 
methyltransferase) RNA down-regulation in the same LVW tissue but not in WT. 
 
Finally we investigated the H3K9Me2 level in neurospheres from the same four 
different genotypes of mice by immuno-blot. Results showed that there was almost no 
H3K9me2 in WT and p53-/- neuropsheres, while a strong H3K9Me2 signal was 
observed in B+p53-/- and a low signal in B+ neurospheres. An up-regulated level of 
H3K9Me2 was also observed in tumor spheres relative to “normal” neurospheres 
generated from the same (B+p53-/-) animal. 
 
In summary, this work suggests major epigenetic disturbances in stem/progenitor cells 
of the pre-neoplastic mouse brain. The findings point to the possibility that these non-
neoplastic but epigenetically disturbed stem/progenitor cells might be the cell-of-origin 
of brain tumors and mechanisms regulating these cells could be crucial targets for 
therapy. The current model is a useful tool to study this possibility further. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The concept of putative cancer stem cells in malignant glioma has inspired many 
studies on stem cell signatures in glioma, the comparison of glioma tumor stem cells 
with normal stem cells and the development of stem cell-based experimental glioma 
therapy. For this purpose, both human tumor tissues and a mouse glioma model have 
been used in this thesis. 
 
The first paper defines two novel phenotypically distinct subsets of glioblastoma 
cultures with different stem-like properties. In the paper, SOX2 is identified as a key 
regulator of the Type A cultures, which have a more profound capacity for tumor 
formation in vivo and self-renewal in vitro. Type A cultures are also characterized by a 
gene expression signature similar to that of the recently described 
proneural/classical/neural subsets of glioblastoma, whereas type B cultures are more 
related to the mesenchymal subset. Additionally, the findings that the resistance of type 
A cultures to mono-treatment with PDGF- and IGF-1-receptor inhibitors could be 
overcome by combination treatment with the two inhibitors, are highly relevant to 
ongoing efforts to develop cancer stem cell-targeting therapies. It is highly temping to 
design a future clinical study based on combined gene expression analysis, selected 
gene mutation profiles and selective treatment regimens. The mesenchymal subset 
(similar to type B cultures) would be assigned to either PDGF- or IGF-1-receptor 
inhibitor, whilst the rest (resembling type A cultures) would be assigned to combination 
treatment. At the same time, it would be highly interesting to learn the effect of the 
combination vs. mono-treatment on the intra-celluar signaling pathways in the glioma 
cells. 
 
In the second paper, deregulated expression of neural and pluripotent stem cell 
regulatory proteins Sox2, Oct4, Nanog and Klf4 was demonstrated in human malignant 
gliomas. The presence of the four factors correlated with increased malignancy of 
human glioma. Results also showed that the expression of this pluripotency gene 
signature in brain cancer cells is largely dependent on signals in the microenvironment. 
Further studies are needed to address the exact role of these stem cell regulators in 
gliomas and the environmental signals regulating them. Are these pluripotency factors 
important for glioma tumorigenesis? If so, these proteins might constitute relevant 
targets for therapeutic strategies aiming to prevent growth and recurrence of tumors. 
 
The third paper describes a significantly elevated level of histone3 lysine9 methylation 
and global DNA hypomethylation in the pre-neoplastic stage of a mouse brain tumor 
model. This model was generated by astrocyte and astrocyte progenitor/stem cell-
specific over expression of PDGFB combined with a p53 null background. The DNA 
hypomethylation was seen in the pre-neoplastic brain especially in the morphologically 
normal LVW of the lateral ventricles where neural stem/progenitor cells are known to 
be located, as well as in mouse glioma samples. This is the first work describing 
epigenetic changes of precursor cells during the pre-neoplastic stage using an animal 
model. The combinatorial effect of PDGFB expression and p53 loss of function seems 
to lead to epigenetic alterations of the neural stem/progenitor cell niche and may also 
set the stage for later transformation to cancer cells. The exact mechanism of this 
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epigenetic change is still unknown. By analyzing for potential genetic changes, such as 
gene copy number changes and whole epi-genome analyses of the tumor material and 
the NSC region, we hope to gain valuable data leading to a better understanding of the 
underlining mechanisms and new potentials for future glioma targeted therapy.  
 
In summary, this thesis has presented connections between stem cells and glioma in 
different aspects such as gene expression signatures, stem cell features as a potential 
resistance mechanism to targeted therapies and epigenetic alterations in a stem cell 
niche of the pre-neoplastic mouse brain. A better understanding of different self-
renewing stem cell populations within gliomas is lending more and more insights into 
the mechanisms of gliomagenesis and may ultimately lead to new approaches for more 
personalized stem cell based glioma treatment. 
  32 
5 ACKNOWLEDGEMENTS 
I would like to sincerely thank all of those who have supported in any aspect to this 
thesis. Special thanks to: 
 
Monica Nistér, my supervisor, for giving me the opportunity to be involved in this 
exciting and challenging brain tumor research field. Thank you for sharing your 
knowledge in tumor biology and pathology, and your enthusiasm to science. Thank you 
for your encouragement, support and trust over the years.  
 
Arne Östman, thank you for many years constructive scientific discussions and 
collaboration, a long story finally with a happy ending! 
 
Johan Holmberg and Jonas Muhr from the Ludwig institute for Cancer Research, many 
thanks for the great collaboration. It was fun working with you. Good luck with your 
science!  
 
Daniel Hägerstrand, for the good collaboration started in Stockholm and continued 
from Boston. Good luck for your future! 
 
Maja Bradic Lindh, for being a good collaborator and a good friend, for sharing 
laughter and tears. Best wishes for your medical practice in Sweden! 
 
Tomas Ekström and Mohsen Karimi from CMM, for the elegant LUMA assay and 
good collaboration. 
 
The clinical crews, Inti Peredo, Abiel Orrego, Bengt Gustavsson, Jurate Skikuniene, 
Göran Hesselager and biobank personnel from Clinical Pathology/Cytology, for 
helping with getting fresh tumor materials and support.  
 
Thanks to all co-authors for contributions to this thesis. Thanks to Jennie Jiang for 
helping with the figure drawing in this thesis. 
 
Members of “ the Mouse group” within Nistér’s group, Anna, Sanna and Inga, for nice 
teamwork over the years! 
 
The past and present members of Nistér’s group: Toota, Peng, Mikael, Karl, Jian, Tong, 
Kaveh, Salah, Joe, Frank, Rong, Maral, Chunde, Mingqi, Xinming, Ulrika, Rona, 
Maggie, Christer, Susanne, Johanna, Teresita (tack för jättegoda kantareller), James 
(for the fantastic car riding and proof-reading of my paper and thesis), thank you all for 
the nice atmosphere and great fun in and outside the lab.   
 
Arne Östman’s group: Janna, Åsa, Christina, Carina, Martin, Markus, Jeroen for always 
being nice and helpful.  
 
Ann-Britt, thank you for all the helping work over the years! 
 
  33 
CCK group members from the 3rd & 4th floor, Liz and Inger in the histology lab, 
administrative and service persons at CCK, thank you all for the help. 
 
Rolf Ohlsson and Susan Pfeifer, thank you for introducing me the field of epigenetics 
and giving me the first lesson about molecular tumor biology and cancer epigenetics. 
 
Andy Feinberg, for hosting me in your lab at Hopkins in Baltimore and for the on-
going collaboration and helpful discussions. 
 
Hengmi, thank you for all the encouragements and help in Uppsala and Baltimore. 
 
Gary, Gail and Rats, for so many years’ Christmas greetings, no matter where I am in 
the world. I always miss the time in Uppsala! 
 
Zou Xiang, thank you for encouraging me to come back to Sweden for PhD and for 
friendship. Best wishes for your science!  
 
Jianman, Chao and Xingjian, for all the encouragements and support over the years. 
Xingjian is now Jennie’s role model. 
 
Donghui’s family, Donghui, Dejiu and Ellen, thank you for all the fun time together!  
 
Hengmi, Liangmei and family, Yiming, Yijia and family, for friendship and great time 
both in Uppsala and Baltimore! 
 
My family in China, my parents, He Qi and Xiao Yu; my brother’s family, Xiaoqi, 
Yanyan and Jinglei; my mother-in-law, Yulan and sister-in-law’s family, Yan, Junbao 
and Jingjing, thank you for always being there and support. 
 
Finally, my beloved husband Su ♥ and daughter Jennie ♥, for love, patience and 
support. I wouldn’t have made it without you! 
 
  34 
6 REFERENCES 
 
 
 
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, 
R., Bilic, J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of 
induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276-
1284. 
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. 
(2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad 
Sci U S A 100, 3983-3988. 
Alcantara Llaguno, S., Chen, J., Kwon, C. H., Jackson, E. L., Li, Y., Burns, D. K., 
Alvarez-Buylla, A., and Parada, L. F. (2009). Malignant astrocytomas originate from 
neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 
15, 45-56. 
Altman, J., and Das, G. D. (1965). Autoradiographic and histological evidence of 
postnatal hippocampal neurogenesis in rats. J Comp Neurol 124, 319-335. 
Alvarez-Buylla, A., and Lim, D. A. (2004). For the long run: maintaining germinal 
niches in the adult brain. Neuron 41, 683-686. 
Amatya, V. J., Naumann, U., Weller, M., and Ohgaki, H. (2005). TP53 promoter 
methylation in human gliomas. Acta Neuropathol 110, 178-184. 
Asklund T, B. O., Malmström A, Blomquist E and Henriksson R (2012). Överlevnaden 
vid maligna gliom har ökat senaste tio åren. Läkartidningen 109, 875-878. 
Avilion, A. A., Nicolis, S. K., Pevny, L. H., Perez, L., Vivian, N., and Lovell-Badge, R. 
(2003). Multipotent cell lineages in early mouse development depend on SOX2 
function. Genes Dev 17, 126-140. 
Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2003). PTEN 
methylation and expression in glioblastomas. Acta Neuropathol 106, 479-485. 
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., and von Deimling, A. 
(2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 
116, 597-602. 
Banerjee, C. (2011). Stem cells therapies in basic science and translational medicine: 
current status and treatment monitoring strategies. Curr Pharm Biotechnol 12, 469-487. 
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., 
McLendon, R. E., Bigner, D. D., and Rich, J. N. (2006). Stem cell-like glioma cells 
promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 
66, 7843-7848. 
Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., Piccirillo, S., 
Vescovi, A. L., DiMeco, F., Olivi, A., and Eberhart, C. G. (2007). Cyclopamine-
mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. 
Stem Cells 25, 2524-2533. 
Barami, K., Sloan, A. E., Rojiani, A., Schell, M. J., Staller, A., and Brem, S. (2009). 
Relationship of gliomas to the ventricular walls. J Clin Neurosci 16, 195-201. 
  35 
Baylin, S. B., and Jones, P. A. (2011). A decade of exploring the cancer epigenome - 
biological and translational implications. Nat Rev Cancer 11, 726-734. 
Beattie, G. M., Lopez, A. D., Bucay, N., Hinton, A., Firpo, M. T., King, C. C., and 
Hayek, A. (2005). Activin A maintains pluripotency of human embryonic stem cells in 
the absence of feeder layers. Stem Cells 23, 489-495. 
Behin, A., Hoang-Xuan, K., Carpentier, A. F., and Delattre, J. Y. (2003). Primary brain 
tumours in adults. Lancet 361, 323-331. 
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P. J., 
Aigner, L., Brawanski, A., Bogdahn, U., and Beier, C. P. (2007). CD133(+) and 
CD133(-) glioblastoma-derived cancer stem cells show differential growth 
characteristics and molecular profiles. Cancer Res 67, 4010-4015. 
Bello, M. J., and Rey, J. A. (2006). The p53/Mdm2/p14ARF cell cycle control pathway 
genes may be inactivated by genetic and epigenetic mechanisms in gliomas. Cancer 
Genet Cytogenet 164, 172-173. 
Ben-David, U., and Benvenisty, N. (2011). The tumorigenicity of human embryonic 
and induced pluripotent stem cells. Nat Rev Cancer 11, 268-277. 
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., and 
Weinberg, R. A. (2008). An embryonic stem cell-like gene expression signature in 
poorly differentiated aggressive human tumors. Nat Genet 40, 499-507. 
Biernat, W., Huang, H., Yokoo, H., Kleihues, P., and Ohgaki, H. (2004). Predominant 
expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 
14, 131-136. 
Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. (1997). Amplification and 
overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp 
Neurol 56, 180-185. 
Bigner, S. H., Matthews, M. R., Rasheed, B. K., Wiltshire, R. N., Friedman, H. S., 
Friedman, A. H., Stenzel, T. T., Dawes, D. M., McLendon, R. E., and Bigner, D. D. 
(1999). Molecular genetic aspects of oligodendrogliomas including analysis by 
comparative genomic hybridization. Am J Pathol 155, 375-386. 
Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-737. 
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., 
Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., et al. (2005). Core 
transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-956. 
Bradley, A., Evans, M., Kaufman, M. H., and Robertson, E. (1984). Formation of 
germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309, 255-
256. 
Brennan, C. (2011). Genomic profiles of glioma. Curr Neurol Neurosci Rep 11, 291-
297. 
Bruna, A., Darken, R. S., Rojo, F., Ocana, A., Penuelas, S., Arias, A., Paris, R., 
Tortosa, A., Mora, J., Baselga, J., and Seoane, J. (2007). High TGFbeta-Smad activity 
confers poor prognosis in glioma patients and promotes cell proliferation depending on 
the methylation of the PDGF-B gene. Cancer Cell 11, 147-160. 
Bylund, M., Andersson, E., Novitch, B. G., and Muhr, J. (2003). Vertebrate 
neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 6, 1162-1168. 
  36 
Cadieux, B., Ching, T. T., VandenBerg, S. R., and Costello, J. F. (2006). Genome-wide 
hypomethylation in human glioblastomas associated with specific copy number 
alteration, methylenetetrahydrofolate reductase allele status, and increased 
proliferation. Cancer Res 66, 8469-8476. 
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, 
R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998). Specific 
genetic predictors of chemotherapeutic response and survival in patients with anaplastic 
oligodendrogliomas. J Natl Cancer Inst 90, 1473-1479. 
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. 
Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007). A perivascular niche for 
brain tumor stem cells. Cancer Cell 11, 69-82. 
Campos, B., Bermejo, J. L., Han, L., Felsberg, J., Ahmadi, R., Grabe, N., Reifenberger, 
G., Unterberg, A., and Herold-Mende, C. (2011). Expression of nuclear receptor 
corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102, 
387-392. 
Capecchi, M. R. (2005). Gene targeting in mice: functional analysis of the mammalian 
genome for the twenty-first century. Nat Rev Genet 6, 507-512. 
CBTRUS (2011). CBTRUS satistical report: Primary brain and central nerous system 
tumors diagnosed in the United States in 2004-2007. Central Brain Tumor registry of 
the United States. 
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., and Smith, A. 
(2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in 
embryonic stem cells. Cell 113, 643-655. 
Charles, N., Ozawa, T., Squatrito, M., Bleau, A. M., Brennan, C. W., Hambardzumyan, 
D., and Holland, E. C. (2010). Perivascular nitric oxide activates notch signaling and 
promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141-
152. 
Chen, J., McKay, R. M., and Parada, L. F. (2012). Malignant glioma: lessons from 
genomics, mouse models, and stem cells. Cell 149, 36-47. 
Clarke, L., and van der Kooy, D. (2009). Low oxygen enhances primitive and definitive 
neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells 
27, 1879-1886. 
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., Jones, D. L., 
Visvader, J., Weissman, I. L., and Wahl, G. M. (2006). Cancer stem cells--perspectives 
on current status and future directions: AACR Workshop on cancer stem cells. Cancer 
Res 66, 9339-9344. 
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., and Maitland, N. J. (2005). 
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 
10946-10951. 
Costello, J. F., Berger, M. S., Huang, H. S., and Cavenee, W. K. (1996). Silencing of 
p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. 
Cancer Res 56, 2405-2410. 
Dahlstrand, J., Collins, V. P., and Lendahl, U. (1992). Expression of the class VI 
intermediate filament nestin in human central nervous system tumors. Cancer Res 52, 
5334-5341. 
  37 
Ding, H., Roncari, L., Shannon, P., Wu, X., Lau, N., Karaskova, J., Gutmann, D. H., 
Squire, J. A., Nagy, A., and Guha, A. (2001). Astrocyte-specific expression of activated 
p21-ras results in malignant astrocytoma formation in a transgenic mouse model of 
human gliomas. Cancer Res 61, 3826-3836. 
Dresemann, G. (2005). Imatinib and hydroxyurea in pretreated progressive 
glioblastoma multiforme: a patient series. Ann Oncol 16, 1702-1708. 
Du, Z., Jia, D., Liu, S., Wang, F., Li, G., Zhang, Y., Cao, X., Ling, E. A., and Hao, A. 
(2009). Oct4 is expressed in human gliomas and promotes colony formation in glioma 
cells. Glia 57, 724-733. 
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., 
Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012). Emerging 
insights into the molecular and cellular basis of glioblastoma. Genes Dev 26, 756-784. 
Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal instability 
and tumors promoted by DNA hypomethylation. Science 300, 455. 
Ehrlich, M. (2002). DNA methylation in cancer: too much, but also too little. Oncogene 
21, 5400-5413. 
Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., 
Ruco, L., Peschle, C., and De Maria, R. (2008). Identification and expansion of the 
tumorigenic lung cancer stem cell population. Cell Death Differ 15, 504-514. 
Eriksson, P. S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A. M., Nordborg, C., 
Peterson, D. A., and Gage, F. H. (1998). Neurogenesis in the adult human 
hippocampus. Nat Med 4, 1313-1317. 
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., and Herman, J. G. (1999). 
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by 
promoter hypermethylation is a common event in primary human neoplasia. Cancer 
Res 59, 793-797. 
Evans, M. J., and Kaufman, M. H. (1981). Establishment in culture of pluripotential 
cells from mouse embryos. Nature 292, 154-156. 
Favaro, R., Valotta, M., Ferri, A. L., Latorre, E., Mariani, J., Giachino, C., Lancini, C., 
Tosetti, V., Ottolenghi, S., Taylor, V., and Nicolis, S. K. (2009). Hippocampal 
development and neural stem cell maintenance require Sox2-dependent regulation of 
Shh. Nat Neurosci 12, 1248-1256. 
Feinberg, A. P., and Tycko, B. (2004). The history of cancer epigenetics. Nat Rev 
Cancer 4, 143-153. 
Ferri, A. L., Cavallaro, M., Braida, D., Di Cristofano, A., Canta, A., Vezzani, A., 
Ottolenghi, S., Pandolfi, P. P., Sala, M., DeBiasi, S., and Nicolis, S. K. (2004). Sox2 
deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse 
brain. Development 131, 3805-3819. 
Fleming, T. P., Saxena, A., Clark, W. C., Robertson, J. T., Oldfield, E. H., Aaronson, S. 
A., and Ali, I. U. (1992). Amplification and/or overexpression of platelet-derived 
growth factor receptors and epidermal growth factor receptor in human glial tumors. 
Cancer Res 52, 4550-4553. 
Fraga, M. F., Herranz, M., Espada, J., Ballestar, E., Paz, M. F., Ropero, S., Erkek, E., 
Bozdogan, O., Peinado, H., Niveleau, A., et al. (2004). A mouse skin multistage 
carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. 
Cancer Res 64, 5527-5534. 
  38 
Fuentealba, L. C., Obernier, K., and Alvarez-Buylla, A. (2012). Adult neural stem cells 
bridge their niche. Cell Stem Cell 10, 698-708. 
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., 
Foroni, C., Dimeco, F., and Vescovi, A. (2004). Isolation and characterization of 
tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64, 
7011-7021. 
Gan, H. K., Kaye, A. H., and Luwor, R. B. (2009). The EGFRvIII variant in 
glioblastoma multiforme. J Clin Neurosci 16, 748-754. 
Gangemi, R. M., Griffero, F., Marubbi, D., Perera, M., Capra, M. C., Malatesta, P., 
Ravetti, G. L., Zona, G. L., Daga, A., and Corte, G. (2009). SOX2 silencing in 
glioblastoma tumor-initiating cells causes stop of proliferation and loss of 
tumorigenicity. Stem Cells 27, 40-48. 
Gil-Perotin, S., Marin-Husstege, M., Li, J., Soriano-Navarro, M., Zindy, F., Roussel, 
M. F., Garcia-Verdugo, J. M., and Casaccia-Bonnefil, P. (2006). Loss of p53 induces 
changes in the behavior of subventricular zone cells: implication for the genesis of glial 
tumors. J Neurosci 26, 1107-1116. 
Graham, V., Khudyakov, J., Ellis, P., and Pevny, L. (2003). SOX2 functions to 
maintain neural progenitor identity. Neuron 39, 749-765. 
Gupta, P. B., Chaffer, C. L., and Weinberg, R. A. (2009). Cancer stem cells: mirage or 
reality? Nat Med 15, 1010-1012. 
Haffner, M. C., Chaux, A., Meeker, A. K., Esopi, D. M., Gerber, J., Pellakuru, L. G., 
Toubaji, A., Argani, P., Iacobuzio-Donahue, C., Nelson, W. G., et al. (2011). Global 5-
hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell 
compartments and in human cancers. Oncotarget 2, 627-637. 
Hagerstrand, D., He, X., Bradic Lindh, M., Hoefs, S., Hesselager, G., Ostman, A., and 
Nister, M. (2011). Identification of a SOX2-dependent subset of tumor- and sphere-
forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. 
Neuro Oncol 13, 1178-1191. 
Hanna, J., Wernig, M., Markoulaki, S., Sun, C. W., Meissner, A., Cassady, J. P., Beard, 
C., Brambrink, T., Wu, L. C., Townes, T. M., and Jaenisch, R. (2007). Treatment of 
sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 
318, 1920-1923. 
Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., 
Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005). MGMT gene 
silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-
1003. 
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., 
Bronner-Fraser, M., and Kornblum, H. I. (2003). Cancerous stem cells can arise from 
pediatric brain tumors. Proc Natl Acad Sci U S A 100, 15178-15183. 
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, 
C. J., and Heeschen, C. (2007). Distinct populations of cancer stem cells determine 
tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 
313-323. 
Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C. H., 
Westermark, B., and Nister, M. (1992). Platelet-derived growth factor and its receptors 
in human glioma tissue: expression of messenger RNA and protein suggests the 
presence of autocrine and paracrine loops. Cancer Res 52, 3213-3219. 
  39 
Hermanson, M., Funa, K., Koopmann, J., Maintz, D., Waha, A., Westermark, B., 
Heldin, C. H., Wiestler, O. D., Louis, D. N., von Deimling, A., and Nister, M. (1996). 
Association of loss of heterozygosity on chromosome 17p with high platelet-derived 
growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56, 
164-171. 
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., and Fuller, G. N. 
(2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma 
formation in mice. Nat Genet 25, 55-57. 
Holland, E. C., Hively, W. P., DePinho, R. A., and Varmus, H. E. (1998). A 
constitutively active epidermal growth factor receptor cooperates with disruption of G1 
cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-
3685. 
Holland, E. C., and Varmus, H. E. (1998). Basic fibroblast growth factor induces cell 
migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci 
U S A 95, 1218-1223. 
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in 
human cancers. Science 253, 49-53. 
Holmberg, J., He, X., Peredo, I., Orrego, A., Hesselager, G., Ericsson, C., Hovatta, O., 
Oba-Shinjo, S. M., Marie, S. K., Nister, M., and Muhr, J. (2011). Activation of neural 
and pluripotent stem cell signatures correlates with increased malignancy in human 
glioma. PLoS One 6, e18454. 
Hu, X., Pandolfi, P. P., Li, Y., Koutcher, J. A., Rosenblum, M., and Holland, E. C. 
(2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT 
signaling in glioblastoma. Neoplasia 7, 356-368. 
Huse, J. T., Phillips, H. S., and Brennan, C. W. (2011). Molecular subclassification of 
diffuse gliomas: seeing order in the chaos. Glia 59, 1190-1199. 
Inda, M. M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W., Vandenberg, S., 
Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., et al. (2010). Tumor 
heterogeneity is an active process maintained by a mutant EGFR-induced cytokine 
circuit in glioblastoma. Genes Dev 24, 1731-1745. 
Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., 
Gabo, K., Rongione, M., Webster, M., et al. (2009). The human colon cancer 
methylome shows similar hypo- and hypermethylation at conserved tissue-specific 
CpG island shores. Nat Genet 41, 178-186. 
Issa, J. P. (2004). CpG island methylator phenotype in cancer. Nat Rev Cancer 4, 988-
993. 
Jackson, E. L., Garcia-Verdugo, J. M., Gil-Perotin, S., Roy, M., Quinones-Hinojosa, 
A., VandenBerg, S., and Alvarez-Buylla, A. (2006). PDGFR alpha-positive B cells are 
neural stem cells in the adult SVZ that form glioma-like growths in response to 
increased PDGF signaling. Neuron 51, 187-199. 
Jacques, T. S., Swales, A., Brzozowski, M. J., Henriquez, N. V., Linehan, J. M., 
Mirzadeh, Z., C, O. M., Naumann, H., Alvarez-Buylla, A., and Brandner, S. (2010). 
Combinations of genetic mutations in the adult neural stem cell compartment determine 
brain tumour phenotypes. Embo J 29, 222-235. 
Jin, S. G., Jiang, Y., Qiu, R., Rauch, T. A., Wang, Y., Schackert, G., Krex, D., Lu, Q., 
and Pfeifer, G. P. (2011). 5-Hydroxymethylcytosine Is Strongly Depleted in Human 
Cancers but Its Levels Do Not Correlate with IDH1 Mutations. Cancer Res. 
  40 
Jones, P. A., and Baylin, S. B. (2007). The epigenomics of cancer. Cell 128, 683-692. 
Joo, K. M., Kim, S. Y., Jin, X., Song, S. Y., Kong, D. S., Lee, J. I., Jeon, J. W., Kim, 
M. H., Kang, B. G., Jung, Y., et al. (2008). Clinical and biological implications of 
CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88, 808-815. 
Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A., Fack, F., Thorsen, F., 
Taxt, T., Bartos, M., Jirik, R., et al. (2011). Anti-VEGF treatment reduces blood supply 
and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108, 
3749-3754. 
Kim, J. B., Greber, B., Arauzo-Bravo, M. J., Meyer, J., Park, K. I., Zaehres, H., and 
Scholer, H. R. (2009). Direct reprogramming of human neural stem cells by OCT4. 
Nature 461, 649-643. 
Knobbe, C. B., Merlo, A., and Reifenberger, G. (2002). Pten signaling in gliomas. 
Neuro Oncol 4, 196-211. 
Koh, K. P., Yabuuchi, A., Rao, S., Huang, Y., Cunniff, K., Nardone, J., Laiho, A., 
Tahiliani, M., Sommer, C. A., Mostoslavsky, G., et al. (2011). Tet1 and Tet2 regulate 
5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic 
stem cells. Cell Stem Cell 8, 200-213. 
Laird, P. W. (2003). The power and the promise of DNA methylation markers. Nat Rev 
Cancer 3, 253-266. 
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., 
Minden, M., Paterson, B., Caligiuri, M. A., and Dick, J. E. (1994). A cell initiating 
human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-
648. 
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, 
B. W., Christopher, N., Zhang, W., et al. (2006). Tumor stem cells derived from 
glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and 
genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403. 
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., 
Clarke, M. F., and Simeone, D. M. (2007). Identification of pancreatic cancer stem 
cells. Cancer Res 67, 1030-1037. 
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., 
Lathia, J., McLendon, R. E., et al. (2009). Hypoxia-inducible factors regulate 
tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513. 
Li, Z., Lee, J. W., Mukherjee, D., Ji, J., Jeswani, S. P., Black, K. L., and Yu, J. S. 
(2012). Immunotherapy targeting glioma stem cells--insights and perspectives. Expert 
Opin Biol Ther 12, 165-178. 
Liu, B. L., Cheng, J. X., Zhang, X., Wang, R., Zhang, W., Lin, H., Xiao, X., Cai, S., 
Chen, X. Y., and Cheng, H. (2010). Global histone modification patterns as prognostic 
markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev 19, 2888-2896. 
Liu, C., Sage, J. C., Miller, M. R., Verhaak, R. G., Hippenmeyer, S., Vogel, H., 
Foreman, O., Bronson, R. T., Nishiyama, A., Luo, L., and Zong, H. (2011). Mosaic 
analysis with double markers reveals tumor cell of origin in glioma. Cell 146, 209-221. 
Loh, Y. H., Wu, Q., Chew, J. L., Vega, V. B., Zhang, W., Chen, X., Bourque, G., 
George, J., Leong, B., Liu, J., et al. (2006). The Oct4 and Nanog transcription network 
regulates pluripotency in mouse embryonic stem cells. Nat Genet 38, 431-440. 
  41 
Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A., and Giese, N. A. 
(2002). Platelet-derived growth factor (PDGF) autocrine signaling regulates survival 
and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and 
PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62, 
3729-3735. 
Louis DN, O. H., Wiestler OD, Cavenee WK (2007). WHO classification of tumours of 
the central nervous system, 4th edn (Lyon). 
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., 
Scheithauer, B. W., and Kleihues, P. (2007). The 2007 WHO classification of tumours 
of the central nervous system. Acta Neuropathol 114, 97-109. 
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, 
A. T., and Plath, K. (2008). Generation of human induced pluripotent stem cells from 
dermal fibroblasts. Proc Natl Acad Sci U S A 105, 2883-2888. 
Lu, B., Malcuit, C., Wang, S., Girman, S., Francis, P., Lemieux, L., Lanza, R., and 
Lund, R. (2009). Long-term safety and function of RPE from human embryonic stem 
cells in preclinical models of macular degeneration. Stem Cells 27, 2126-2135. 
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, 
C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012). IDH mutation impairs 
histone demethylation and results in a block to cell differentiation. Nature 483, 474-
478. 
Lucio-Eterovic, A. K., Cortez, M. A., Valera, E. T., Motta, F. J., Queiroz, R. G., 
Machado, H. R., Carlotti, C. G., Jr., Neder, L., Scrideli, C. A., and Tone, L. G. (2008). 
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and 
normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 
8, 243. 
Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the 
National Academy of Sciences of the United States of America 78, 7634-7638. 
Marumoto, T., Tashiro, A., Friedmann-Morvinski, D., Scadeng, M., Soda, Y., Gage, F. 
H., and Verma, I. M. (2009). Development of a novel mouse glioma model using 
lentiviral vectors. Nat Med 15, 110-116. 
Masui, S., Nakatake, Y., Toyooka, Y., Shimosato, D., Yagi, R., Takahashi, K., Okochi, 
H., Okuda, A., Matoba, R., Sharov, A. A., et al. (2007). Pluripotency governed by Sox2 
via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9, 
625-635. 
McDonald, O. G., Wu, H., Timp, W., Doi, A., and Feinberg, A. P. (2011). Genome-
scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat 
Struct Mol Biol 18, 867-874. 
Meletis, K., Wirta, V., Hede, S. M., Nister, M., Lundeberg, J., and Frisen, J. (2006). 
p53 suppresses the self-renewal of adult neural stem cells. Development 133, 363-369. 
Mellinghoff, I. K., Lassman, A. B., and Wen, P. Y. (2011). Signal transduction 
inhibitors and antiangiogenic therapies for malignant glioma. Glia 59, 1205-1212. 
Ming, G. L., and Song, H. (2011). Adult neurogenesis in the mammalian brain: 
significant answers and significant questions. Neuron 70, 687-702. 
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., 
Maruyama, M., Maeda, M., and Yamanaka, S. (2003). The homeoprotein Nanog is 
  42 
required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 631-
642. 
Mohyeldin, A., Garzon-Muvdi, T., and Quinones-Hinojosa, A. (2010). Oxygen in stem 
cell biology: a critical component of the stem cell niche. Cell Stem Cell 7, 150-161. 
Nagarajan, R. P., and Costello, J. F. (2009). Epigenetic mechanisms in glioblastoma 
multiforme. Semin Cancer Biol 19, 188-197. 
Nakamura, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2001). Promoter 
hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81, 77-82. 
Ng, H. H., and Surani, M. A. (2011). The transcriptional and signalling networks of 
pluripotency. Nat Cell Biol 13, 490-496. 
Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., 
Scholer, H., and Smith, A. (1998). Formation of pluripotent stem cells in the 
mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-391. 
Nister, M., Heldin, C. H., Wasteson, A., and Westermark, B. (1982). A platelet-derived 
growth factor analog produced by a human clonal glioma cell line. Ann N Y Acad Sci 
397, 25-33. 
Nister, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson-Welsh, L., 
Heldin, C. H., Schlessinger, J., and Westermark, B. (1988). Expression of messenger 
RNAs for platelet-derived growth factor and transforming growth factor-alpha and their 
receptors in human malignant glioma cell lines. Cancer Res 48, 3910-3918. 
Niwa, H., Miyazaki, J., and Smith, A. G. (2000). Quantitative expression of Oct-3/4 
defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-
376. 
Norden, A. D., Drappatz, J., and Wen, P. Y. (2009). Antiangiogenic therapies for high-
grade glioma. Nat Rev Neurol 5, 610-620. 
Northcott, P. A., Nakahara, Y., Wu, X., Feuk, L., Ellison, D. W., Croul, S., Mack, S., 
Kongkham, P. N., Peacock, J., Dubuc, A., et al. (2009). Multiple recurrent genetic 
events converge on control of histone lysine methylation in medulloblastoma. Nat 
Genet 41, 465-472. 
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. 
P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010). Identification of a 
CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer 
Cell 17, 510-522. 
O'Brien, C. A., Pollett, A., Gallinger, S., and Dick, J. E. (2007). A human colon cancer 
cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-
110. 
Ogden, A. T., Waziri, A. E., Lochhead, R. A., Fusco, D., Lopez, K., Ellis, J. A., Kang, 
J., Assanah, M., McKhann, G. M., Sisti, M. B., et al. (2008). Identification of 
A2B5+CD133- tumor-initiating cells in adult human gliomas. NEUROSURGERY 62, 
505-514; discussion 514-505. 
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P. L., 
Burkhard, C., Schuler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004). Genetic 
pathways to glioblastoma: a population-based study. Cancer Res 64, 6892-6899. 
  43 
Ohgaki, H., and Kleihues, P. (2005). Population-based studies on incidence, survival 
rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol 
Exp Neurol 64, 479-489. 
Ohgaki, H., and Kleihues, P. (2007). Genetic pathways to primary and secondary 
glioblastoma. Am J Pathol 170, 1445-1453. 
Ohgaki, H., and Kleihues, P. (2011). Genetic profile of astrocytic and oligodendroglial 
gliomas. Brain Tumor Pathol 28, 177-183. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent 
induced pluripotent stem cells. Nature 448, 313-317. 
Ostrom, Q. T., and Barnholtz-Sloan, J. S. (2011). Current state of our knowledge on 
brain tumor epidemiology. Curr Neurol Neurosci Rep 11, 329-335. 
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, 
P., Carter, H., Siu, I. M., Gallia, G. L., et al. (2008). An integrated genomic analysis of 
human glioblastoma multiforme. Science 321, 1807-1812. 
Pastrana, E., Silva-Vargas, V., and Doetsch, F. (2011). Eyes wide open: a critical 
review of sphere-formation as an assay for stem cells. Cell Stem Cell 8, 486-498. 
Pesce, M., and Scholer, H. R. (2001). Oct-4: gatekeeper in the beginnings of 
mammalian development. Stem Cells 19, 271-278. 
Pevny, L., and Placzek, M. (2005). SOX genes and neural progenitor identity. Curr 
Opin Neurobiol 15, 7-13. 
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., 
Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006). Molecular subclasses 
of high-grade glioma predict prognosis, delineate a pattern of disease progression, and 
resemble stages in neurogenesis. Cancer Cell 9, 157-173. 
Piccirillo, S. G., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., 
Brem, H., Olivi, A., Dimeco, F., and Vescovi, A. L. (2006). Bone morphogenetic 
proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 
444, 761-765. 
Rahman, M., Deleyrolle, L., Vedam-Mai, V., Azari, H., Abd-El-Barr, M., and 
Reynolds, B. A. (2011). The cancer stem cell hypothesis: failures and pitfalls. 
NEUROSURGERY 68, 531-545; discussion 545. 
Raya, A., Rodriguez-Piza, I., Guenechea, G., Vassena, R., Navarro, S., Barrero, M. J., 
Consiglio, A., Castella, M., Rio, P., Sleep, E., et al. (2009). Disease-corrected 
haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. 
Nature 460, 53-59. 
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, S., Vredenburgh, 
J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., 2nd, et al. 
(2005). Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent 
glioblastoma multiforme. J Clin Oncol 23, 9359-9368. 
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. (1993). 
Amplification and overexpression of the MDM2 gene in a subset of human malignant 
gliomas without p53 mutations. Cancer Res 53, 2736-2739. 
Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E., and Jacks, T. (2000). 
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. 
Nat Genet 26, 109-113. 
  44 
Reynolds, B. A., and Weiss, S. (1992). Generation of neurons and astrocytes from 
isolated cells of the adult mammalian central nervous system. Science 255, 1707-1710. 
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., 
and De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating 
cells. Nature 445, 111-115. 
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, 
G., Parati, E. A., Stassi, G., Larocca, L. M., and De Maria, R. (2010). Tumour 
vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 
468, 824-828. 
Richards, L. J., Kilpatrick, T. J., and Bartlett, P. F. (1992). De novo generation of 
neuronal cells from the adult mouse brain. Proc Natl Acad Sci U S A 89, 8591-8595. 
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., 
Walker, D., Zhang, W. R., Kreitzer, A. C., and Huang, Y. (2012). Direct 
reprogramming of mouse and human fibroblasts into multipotent neural stem cells with 
a single factor. Cell Stem Cell 11, 100-109. 
Robertson, T., Koszyca, B., and Gonzales, M. (2011). Overview and recent advances in 
neuropathology. Part 1: Central nervous system tumours. Pathology 43, 88-92. 
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, 
A., Powell, S. M., Riggins, G. J., et al. (2004). High frequency of mutations of the 
PIK3CA gene in human cancers. Science 304, 554. 
Sathornsumetee, S., and Rich, J. N. (2008). Designer therapies for glioblastoma 
multiforme. Ann N Y Acad Sci 1142, 108-132. 
Scaffidi, P., and Misteli, T. (2011). In vitro generation of human cells with cancer stem 
cell properties. Nat Cell Biol. 
Scholer, H. R., Ruppert, S., Suzuki, N., Chowdhury, K., and Gruss, P. (1990). New 
type of POU domain in germ line-specific protein Oct-4. Nature 344, 435-439. 
Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., 
Sturm, D., Fontebasso, A. M., Quang, D. A., Tonjes, M., et al. (2012). Driver 
mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. 
Nature 482, 226-231. 
Seidel, S., Garvalov, B. K., Wirta, V., von Stechow, L., Schanzer, A., Meletis, K., 
Wolter, M., Sommerlad, D., Henze, A. T., Nister, M., et al. (2010). A hypoxic niche 
regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133, 
983-995. 
Sharp, J., Frame, J., Siegenthaler, M., Nistor, G., and Keirstead, H. S. (2010). Human 
embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve 
recovery after cervical spinal cord injury. Stem Cells 28, 152-163. 
Simon, M. C., and Keith, B. (2008). The role of oxygen availability in embryonic 
development and stem cell function. Nat Rev Mol Cell Biol 9, 285-296. 
Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., and 
Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer 
Res 63, 5821-5828. 
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, 
R. M., Cusimano, M. D., and Dirks, P. B. (2004). Identification of human brain tumour 
initiating cells. Nature 432, 396-401. 
  45 
Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M., and 
Rogers, D. (1988). Inhibition of pluripotential embryonic stem cell differentiation by 
purified polypeptides. Nature 336, 688-690. 
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O'Fallon, J., Hosek, S. M., Kimmel, D., 
Yates, A., Burger, P. C., Scheithauer, B. W., and Jenkins, R. B. (2000). Alterations of 
chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, 
astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18, 636-645. 
Sodaa Y, T. M., b, Dinorah Friedmann-Morvinskia, Mie Sodaa, Fei Liua, Hiroyuki 
Michiuec,, and Sandra Pastorinod, M. Y., Robert M. Hoffmane,f, Santosh Kesarid, and 
Inder M. Vermaa,1 (2011). Transdifferentiation of glioblastoma cells into vascular 
endothelial cells. PNAS 108, 4274-4280. 
Son, M. J., Woolard, K., Nam, D. H., Lee, J., and Fine, H. A. (2009). SSEA-1 is an 
enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 
440-452. 
Soussi, T., and Wiman, K. G. (2007). Shaping genetic alterations in human cancer: the 
p53 mutation paradigm. Cancer Cell 12, 303-312. 
Strojnik, T., Rosland, G. V., Sakariassen, P. O., Kavalar, R., and Lah, T. (2007). Neural 
stem cell markers, nestin and musashi proteins, in the progression of human glioma: 
correlation of nestin with prognosis of patient survival. Surg Neurol 68, 133-143; 
discussion 143-134. 
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. 
C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009). Effects of 
radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone 
on survival in glioblastoma in a randomised phase III study: 5-year analysis of the 
EORTC-NCIC trial. Lancet Oncol 10, 459-466. 
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., 
Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005). Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996. 
Stupp, R., and Weller, M. (2010). 2010: neuro-oncology is moving! Curr Opin Neurol 
23, 553-555. 
Suh, H., Consiglio, A., Ray, J., Sawai, T., D'Amour, K. A., and Gage, F. H. (2007). In 
vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural 
stem cells in the adult hippocampus. Cell Stem Cell 1, 515-528. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and 
Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts 
by defined factors. Cell 131, 861-872. 
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from 
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Tavazoie, M., Van der Veken, L., Silva-Vargas, V., Louissaint, M., Colonna, L., Zaidi, 
B., Garcia-Verdugo, J. M., and Doetsch, F. (2008). A specialized vascular niche for 
adult neural stem cells. Cell Stem Cell 3, 279-288. 
TCGA (2008). Comprehensive genomic characterization defines human glioblastoma 
genes and core pathways. Nature 455, 1061-1068. 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., 
Marshall, V. S., and Jones, J. M. (1998). Embryonic stem cell lines derived from 
human blastocysts. Science 282, 1145-1147. 
  46 
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. 
(1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S 
A 96, 8681-8686. 
Uhlmann, K., Rohde, K., Zeller, C., Szymas, J., Vogel, S., Marczinek, K., Thiel, G., 
Nurnberg, P., and Laird, P. W. (2003). Distinct methylation profiles of glioma 
subtypes. Int J Cancer 106, 52-59. 
Uhrbom, L., Dai, C., Celestino, J. C., Rosenblum, M. K., Fuller, G. N., and Holland, E. 
C. (2002). Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural 
progenitors to generate glioblastomas of various morphologies depending on activated 
Akt. Cancer Res 62, 5551-5558. 
Uhrbom, L., Hesselager, G., Nister, M., and Westermark, B. (1998). Induction of brain 
tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. 
Cancer Res 58, 5275-5279. 
van den Bent, M. J. (2010). Interobserver variation of the histopathological diagnosis in 
clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120, 297-304. 
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., and 
Olson, J. J. (2010). Exciting new advances in neuro-oncology: the avenue to a cure for 
malignant glioma. CA Cancer J Clin 60, 166-193. 
Varghese, M., Olstorn, H., Sandberg, C., Vik-Mo, E. O., Noordhuis, P., Nister, M., 
Berg-Johnsen, J., Moe, M. C., and Langmoen, I. A. (2008). A comparison between 
stem cells from the adult human brain and from brain tumors. NEUROSURGERY 63, 
1022-1033; discussion 1033-1024. 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., 
Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010). Integrated genomic 
analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110. 
Vescovi, A. L., Galli, R., and Reynolds, B. A. (2006). Brain tumour stem cells. Nat Rev 
Cancer 6, 425-436. 
Vincent, A., and Van Seuningen, I. (2012). On the epigenetic origin of cancer stem 
cells. Biochim Biophys Acta 1826, 83-88. 
Visvader, J. E. (2011). Cells of origin in cancer. Nature 469, 314-322. 
Visvader, J. E., and Lindeman, G. J. (2012). Cancer stem cells: current status and 
evolving complexities. Cell Stem Cell 10, 717-728. 
Vousden, K. H., and Lane, D. P. (2007). p53 in health and disease. Nat Rev Mol Cell 
Biol 8, 275-283. 
Wang, J., Sakariassen, P. O., Tsinkalovsky, O., Immervoll, H., Boe, S. O., Svendsen, 
A., Prestegarden, L., Rosland, G., Thorsen, F., Stuhr, L., et al. (2008). CD133 negative 
glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J 
Cancer 122, 761-768. 
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., 
Fligelman, B., Leversha, M., Brennan, C., and Tabar, V. (2010). Glioblastoma stem-
like cells give rise to tumour endothelium. Nature 468, 829-833. 
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. Y., 
and Zhu, Y. (2009). Expression of mutant p53 proteins implicates a lineage relationship 
  47 
between neural stem cells and malignant astrocytic glioma in a murine model. Cancer 
Cell 15, 514-526. 
Watanabe, T., Nobusawa, S., Kleihues, P., and Ohgaki, H. (2009). IDH1 mutations are 
early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 
174, 1149-1153. 
Watanabe, T., Yokoo, H., Yokoo, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. 
(2001). Concurrent inactivation of RB1 and TP53 pathways in anaplastic 
oligodendrogliomas. J Neuropathol Exp Neurol 60, 1181-1189. 
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., 
and Hegi, M. E. (2010). MGMT promoter methylation in malignant gliomas: ready for 
personalized medicine? Nat Rev Neurol 6, 39-51. 
Weller, M., Wick, W., and von Deimling, A. (2011). Isocitrate dehydrogenase 
mutations: a challenge to traditional views on the genesis and malignant progression of 
gliomas. Glia 59, 1200-1204. 
Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. N Engl J Med 359, 
492-507. 
Wen, P. Y., Yung, W. K., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. 
E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006). Phase I/II study of imatinib 
mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium 
Study 99-08. Clin Cancer Res 12, 4899-4907. 
Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., 
Wagner, E. F., Metcalf, D., Nicola, N. A., and Gough, N. M. (1988). Myeloid 
leukaemia inhibitory factor maintains the developmental potential of embryonic stem 
cells. Nature 336, 684-687. 
Wu, G., Broniscer, A., McEachron, T. A., Lu, C., Paugh, B. S., Becksfort, J., Qu, C., 
Ding, L., Huether, R., Parker, M., et al. (2012). Somatic histone H3 alterations in 
pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 
44, 251-253. 
Xu, R. H., Peck, R. M., Li, D. S., Feng, X., Ludwig, T., and Thomson, J. A. (2005). 
Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of 
human ES cells. Nat Methods 2, 185-190. 
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H., Ito, S., Yang, C., Xiao, M. 
T., Liu, L. X., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive 
inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30. 
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., 
Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009). IDH1 and IDH2 mutations in 
gliomas. N Engl J Med 360, 765-773. 
Yasuda, H., Soejima, K., Watanabe, H., Kawada, I., Nakachi, I., Yoda, S., Nakayama, 
S., Satomi, R., Ikemura, S., Terai, H., et al. (2010). Distinct epigenetic regulation of 
tumor suppressor genes in putative cancer stem cells of solid tumors. Int J Oncol 37, 
1537-1546. 
Ying, Q. L., Nichols, J., Chambers, I., and Smith, A. (2003). BMP induction of Id 
proteins suppresses differentiation and sustains embryonic stem cell self-renewal in 
collaboration with STAT3. Cell 115, 281-292. 
Young, R. A. (2011). Control of the embryonic stem cell state. Cell 144, 940-954. 
  48 
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, 
S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent 
stem cell lines derived from human somatic cells. Science 318, 1917-1920. 
Zaidi, H. A., Kosztowski, T., DiMeco, F., and Quinones-Hinojosa, A. (2009). Origins 
and clinical implications of the brain tumor stem cell hypothesis. J Neurooncol 93, 49-
60. 
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S. N., Borges, I., and Ruiz i 
Altaba, A. (2010). NANOG regulates glioma stem cells and is essential in vivo acting 
in a cross-functional network with GLI1 and p53. Embo J 29, 2659-2674. 
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, 
Y., et al. (2009). Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic 
activity and induce HIF-1alpha. Science 324, 261-265. 
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A. J., Perry, S. 
R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008). p53 and Pten control neural and 
glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129-1133. 
Zhu, H., Acquaviva, J., Ramachandran, P., Boskovitz, A., Woolfenden, S., Pfannl, R., 
Bronson, R. T., Chen, J. W., Weissleder, R., Housman, D. E., and Charest, A. (2009). 
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in 
gliomagenesis. Proc Natl Acad Sci U S A 106, 2712-2716. 
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A., and 
Parada, L. F. (2005). Early inactivation of p53 tumor suppressor gene cooperating with 
NF1 loss induces malignant astrocytoma. Cancer Cell 8, 119-130. 
 
 
